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Integration of Functional Genomic Data in Genetic Analysis 
Siying Chen 
 
 Identifying disease risk genes is a central topic of human genetics. Cost-effective exome 
and whole genome sequencing enabled large-scale discovery of genetic variations. However, the 
statistical power of finding new risk genes through rare genetic variation is fundamentally 
limited by sample sizes. As a result, we have an incomplete understanding of genetic architecture 
and molecular etiology of most of human conditions and diseases. In this thesis, I developed new 
computational methods that integrate functional genomics data sets, such as epigenomic profiles 
and single-cell transcriptomics, to improve power for identifying genetic risks and gain more 
insights on etiology of developmental disorders. The overall hypothesis that disease risk genes 
contributing to developmental disorders are bottleneck genes under normal development and 
subject to precise transcriptional regulations to maintain spatiotemporal specific expression 
during development. In this thesis I describe two major research projects. The first project, 
Episcore, predicts haploinsufficient genes based on a large integrated epigenomic profiles from 
multiple tissues and cell lines by supervised machine learning methods. The second one, A-risk, 
predicts plausibility of being risk genes of autism spectrum disorder based on single-cell RNA-
seq data collected in human fetal midbrain and prefrontal cortex.  Both methods were shown to 
be able to improve gene discovery in analysis of de novo mutations in developmental disorders. 
 
 
Overall, my thesis represents an effort to integrate functional genomics data by machine learning 
to facilitate both discovery and interpretation of genetic studies of human diseases. We believe 
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Whole genome/exome sequencing (WGS/WES) has been developed to study genetic 
variations, especially effective in detecting mutation associated to genetic disorders. The 
experiments often collected samples in a trio design so mutations only present in child patients 
but not in parents can be identified and further studied on implicated risk genes. Those mutations 
are commonly called as “de novo” mutations. Studies on developmental disorders heavily 
impacted by genetic risk factors found that de novo Loss-of-function (LoF) mutations are indeed 
significant genetic contributions to diseases, such as autism spectrum disorder (ASD) (Iossifov et 
al., 2014) and congenital heart disease (CHD) (Jin et al., 2017). A WES study on de novo 
mutations in autism identified significant contribution from de novo likely-gene disrupting 
mutaitons (LGDs), or commonly called as LoF mutations (Figure 1.1). The enrichment rate of 
LGDs comparing cases and controls is 1.75 (0.21/0.12), which means about 43% LGDs are 
pathogenic variants. While the enrichment rate for missense variants is 1.15 (0.94/0.82), 
Figure 1.1 De novo variants comparison between affected patients and unaffected siblings. The 
event counts for likely-gene disrupting mutations (LGDs) are in the largest discrepancy between cases 
(ASD) and controls (Sib), indicating the contribution of de novo LGD mutations to autism. The figure is 


























indicating only 13% de novo missense variants are pathogenic. However, current statistic power 
has not been sufficient to distinguish the risk variants from the random ones because of limited 
recurrency of those variants (Figure 1.2). A previous study on de novo LGD mutations from 
CHD showed that only a small proportion of LGD variants located in the same gene which is the 
great hurdle to identify risk genes and study disease etiology (Jin et al., 2017). I am going to 
review in section 1.2 on some typical statistic methods developed for risk gene discovery.  
 The work in this thesis took a different perspective from functional genomic data to 
identify disease risk genes rather than utilizing genomic data solely. In the meantime, by 
integrating functional data such as epigenome or single-cell transcriptome, we can impart 
vulnerable cell types or developmental stages specific to a disease altogether. In section 1.3, gene 
dosage sensitivity is reviewed and the most implicated disease mechanism by genetic variants, 
haploinsufficiency has also been illustrated. In the following sections 1.4 and 1.5, I reviewed 
Figure 1.2 Risk gene discovery by recurrence is limited. The number of de novo LGD variants 
contained in each gene shows that only a small proportion of risk genes have recurrent mutations. 
Most risk variants only occur once, which makes it harder to identify. The figure is adapted from Jin 
et al., 2017. 
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how epigenomic modification regulates on transcription, what specific epigenomic patterns in 
haploinsufficient genes have and how important spatiotemporal expression is to development.  
 
1.2 Statistical genetics for risk gene discovery by de novo variants 
 To better utilize WES data and reveal more disease risk genes, an integrated empirical 
Bayesian model, TADA (Transmission And De novo Association), has been developed to 
borrow information across all genes to infer parameters that would be difficult to estimate for 
individual genes. Based on a Hierarchical Bayesian framework, false discovery rate (FDR) for 
each gene can be calculated and the confidence for association between genes and a particular 
disease can be measure by FDR (X. He et al., 2013). 
 In TADA, two major parameters, relative risk of a gene causing a disease γ and the 
proportion of disease risk genes across whole genome π, are estimated by the connection to 
variant fold enrichment (FE), which is calculated as the number of observed variants divided by 
the number of expected. Assuming the background mutation rate for each gene is µ, total number 
of genes in the genome is m and total number of sequenced samples is N, then 
the observed variants, X = πm×2γµN + (1-π)m×2µN 




 = π (γ - 1) + 1, γ ~ Gamma (γ̅ β, β) 
Since FE can be calculated from the data, β was fixed to 1 and estimate γ and π accordingly.  








H1 is alternative hypothesis and H0 is null, where γ = 1. 
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where 𝑷𝑷(𝑯𝑯𝑯𝑯) is estimated π, 𝑷𝑷(𝑯𝑯𝑯𝑯) is (1-π).  
 Assuming 𝑷𝑷(𝑯𝑯𝑯𝑯|𝑿𝑿) is q, 𝑷𝑷(𝑯𝑯𝑯𝑯|𝑿𝑿) is (1- q), the posterior probability of the null model is 





then per-gene based FDR can be calculated from q0, which is the sum of total q0 smaller than the 
current rank divided by the total number of genes with smaller q0.   
 Another Bayesian method, extTADA developed based on the previous TADA and 
enabled estimation of parameters from local gene groups using Markov Chain Monte Carlo 
(MCMC) (Nguyen et al., 2017), which allow stratification of the genome based on prior 
knowledge and parameter estimation can be closer to the true story. We adapted this approach in 
our A-risk project discussed in Chapter 3, for identification of autism risk genes.  
  
1.3 Gene dosage sensitivity 
Dosage-sensitive genes are a subset of genes in our genome that can cause a phenotypic 
effect by a change in gene dosage, either in the way of duplication or deletion (Rice & 
McLysaght, 2017). There are 4 major mechanism of dosage sensitivity of a gene, 
haploinsufficiency, promiscuous off-target interactions at high concentration, dosage balance and 
concentration dependency (Figure 1.3). I am going to discuss each of them in the following.  
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Haploinsufficiency describes a phenomenon where a hemizygous state does not produce 
sufficient gene product for wildtype phenotypes, proposed by Wright as a source of dominant 
negative effects(S. Wright, 1934). This is the most intuitive form of dosage sensitivity, which is 
also the main etiology of de novo loss-of-function (LoF) variants identified through whole 
exome sequencing (WES) and whole genome sequencing (WGS) since most of the variants 
occur in one allele due to extremely low frequency. One well-studied example of 
haploinsufficiency is the 22q11 deletion syndrome, causing serious neural abnormalities such as 
schizophrenia or schizoaffective disorders (Karayiorgou, Simon, & Gogos, 2010). A study on 
protein-coding variation in 60,706 humans measured the depletion of LoF mutations in this 
relatively healthy population and grouped the constraint genes by how much less the observed 
LoF variants compared to the expected (Lek et al., 2016). They defined haploinsufficient genes 
by that the number of observed LoF variants within the gene is less than 10% of the expected and 
they derived a pLI score measuring haploinsufficiency with about 3000 genes in pLI >= 0.9.  
By contrast, the presence of a surplus copy of a wild-type gene can also be deleterious 
(Figure 1.3b). For example, extra copies of the alpha-synuclein gene (SNCA) are associated with 
early-onset Parkinson’s disease, possibly owing to greater protein concentration increasing the 
likelihood of protein aggregation and further precipitating as insoluble amyloid fibrils (Irvine, 





Figure 1.3 A general introduction to gene dosage sensitivity. There are 4 main types 
of dosage sensitivity functional through different mechanisms. Adapted from 
Rice&McLysaght, 2017.  
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  On the other hand, some genes are sensitive to both situation and functioning within a 
concentration balance, which means they cause phenotypes when the copy number either 
increases or decreases. Protein components of large complexes can be particularly dosage-
balanced because incorrect ratios of subunits can devastate the biochemistry of the complex 
assembly, leading to a disfunction of the protein complex. Sometimes a large increase of a 
subunit can result in a decrease in productions of the protein complex, such as the phage HK97 
connector complex assembly (Cardarelli, Maxwell, & Davidson, 2011).  
 While the concentration balance can sometimes become an indicator for gene functions. 
For example, the pyruvate kinase M (PKM) is present in two isoforms during embryonic or adult 
stages. The spliced isoform is dependent on the concentration of hnRNP (heterogeneous nuclear 
ribonucleoproteins) proteins, where the concentration of the splicing regulator determines its 
location of binding and further determines which isoform is produced. A deleterious case is 
found in cancer cells with high concentrations of hnRNP proteins leading to the ectopic 
production of embryonic form (M. Chen, David, & Manley, 2012).  
The study described in Chapter 2 mainly focused on characterization of disease risk 
genes less tolerant to heterozygous mutations, in other words haploinsufficient genes. We found 
specific connections between transcriptional regulation of haploinsufficient genes and 
epigenomic modification, based on which we further predict on additional haploinsufficient 
genes that have been understudied. Discovery on risk genes implicated in other dosage 
sensitivity mechanism is very important, but will definitely require more complicated models, 
which will not be the main topic of the thesis. 
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1.4 Epigenomic regulation 
Epigenomic markers and features have been profiled and studied widely because of 
technical development. They can be generally grouped into six categories: 1. DNA level 
modifications usually occurring at position C5 or N3 on cytosines and N6 on adenines; 2. 
Histone level modifications occurring at more than 130 post-transcriptional modification (PTM) 
sites at the tails of the four core histones (H2A, H2B, H3 and H4); 3. The structurally different 
features such as nucleosome occupancy; 4. The chromatin interactions based on enhancers, 
promotors or insulators interactions; 5. The chromatin domain features profiled by Hi-C allowing 
studies on segmentation of the epigenome; 6.  Non-coding RNA modifications regulating gene 
expression (Stricker, Koferle, & Beck, 2017).  Among the six categories, histone level 
modifications have been the most well-studied (Figure 1.4). Active promotors are commonly 
demarcated by histone H3 lysine 4 dimethylation (H3K4me2), H3K4me3, acetylation (ac) and 
H2A.Z. Transcribed regions are enriched with H3K36me3 and H3K79me2. Repressed genes 
Figure 1.4 Histone modifications and their functions in genomic and transcriptomic 
regulation. Different histone modifications located in various functional genomic regions and 
distinguished functional elements. The figure is adapted from Zhou, Goren, & Bernstein, 2011.  
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may locate within large domains of H3K9me2 or H3K9me3 or H3K27me3. H3K4me1, 
H3K4me2, H3K27ac and the histone acetyltransferase p300 are usually enriched in enhancers. 
CCCTC-binding factors (CTCFs) bind to sites that function as boundary elements, insulators or 
structural scaffolds (Zhou, Goren, & Bernstein, 2011).  
 Histone modifications play an important role in sculping cell-type specific transcription. 
A recent study conducted a proximity ligation-assisted chromatin immunoprecipitation 
sequencing (PLAC-seq) (Fang et al., 2016) to identify chromatin interactions at active promoters 
marked by H3K4me3 in several major neuronal cell types, such as radial glia (RG), intermediate 
progenitor cells (IPCs), excitatory neurons (eNs) and interneurons (iNs) (Song et al., 2020). They 
mapped some key lineage-specific transcription factors’ binding motif to the detected interaction 
regions and found that the motif enrichment aligned in accordance with the role of transcription 
factors in cell-type developmental trajectory. For example, the motifs for DLX1, DLX2, DLX6, 
GSX2 and LHX6 are enriched in interneurons, reflecting their roles in maturation and function 
of interneurons. The broad domains of H3K4me3 markers has also been identified association to 
transcriptional consistency, revealing interplays between histone modifications and 
transcriptional regulation. A previous study measured transcriptional consistency (lower 
transcriptional variability, or “transcriptional noise”) in single cells by calculating the variance in 
expression relative to expression level for each gene in single-cell RNA-seq data sets (Benayoun 
et al., 2014). They found that genes marked by top 5% broadest H3K4me3 domains had reduced 
transcriptional variability across many different cell types, which indicates that H3K4me3 are 
critical for transcriptional precision by ensuring the robustness of transcriptional outputs.   
Haploinsufficient genes are sensitive to expression level change, based on which derived 
a reasonable hypothesis that expression of haploinsufficient genes is under precise transcriptional 
11 
 
regulation. A previous study analyzed thousands of genome-wide epigenetic profiles and found 
that tumor suppressor genes have broad H3K4me3 domains in normal cells (K. Chen et al., 
2015a). Tumor suppressors are often implicated with germline risk in developmental disorders 
through haploinsufficiency (Qi, Dong, Chung, Wang, & Shen, 2016). Previous observations 
suggest that haploinsufficient genes may have specific pattern in epigenomic modifications in 
their functional genomic region, such as broader H3K4me3 peaks, to maintain a highly regulated 
and consistent transcriptomic expression.  
 
1.5 Spatiotemporal gene expression 
During the development of organisms, gene expression programs change over time, 
across differentiation and development, and in response to stimuli as well. A systematic study on 
mRNA microarray profiling of human prefrontal cortex collected the tissue from samples during 
a wide range of development, from fetus to late adulthood (Colantuoni et al., 2011). They 
measured the rate of expression changes in different developmental stages across the lifespan 
using a linear-spine model. The rate of expression change during fetal stages is much higher than 
at adulthood, even compared to the infant stage. However, after a steady platform throughout 
teenage years to the 40s, the rates rise again through several decades. This study vividly depicts 
the dynamics of gene expression on the time scale.  
 Cell-type specific gene expression is nowadays a critical topic in biological studies, 
especially when it comes to human diseases. For example, spatiotemporal expression of 
transcription factors (TFs) can precisely regulate organ development and physiology. A previous 
study on two homeobox transcription factors NKX2-5 and MEIS1 illustrates how spatiotemporal 
expression of TFs precisely regulates cardiogenesis (Dupays et al., 2015). NKX2-5 is also a 
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haploinsufficient gene, mutations in which result in a spectrum of congenital heart disease of 
varying phenotypic penetrance (Akazawa & Komuro, 2005). During cardiac differentiation, the 
two transcription factors have partially overlapping expression patterns, with the result that as 
cardiac progenitors from the anterior heart field differentiate and migrate into the cardiac outflow 
tract, they sequentially experience high levels of MEIS1 and then increasing levels of NKX2-5 
(Figure 1.5). The sequential binding provides a simple regulatory mechanism for a common pool 
of targets of these 2 TFs to regulate cardia development. 
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With the development of Next-generation Sequencing (NGS) technology, people 
nowadays can capture a snapshot of gene expression or transcriptomic profiles in single cells.  
A 
B 
Figure 1.5 Spatial expression of two transcription factors NKX2-5 and MEIS1 in developing 
heart. (A) A graphic illustration of the distribution of two TFs expression. (B) 
Immunohistochemistry of NKX2-5 and MEIS1 on an E8.5 mouse embryo showing their 




Single-cell RNA sequencing is a powerful innovation that people can identify cell types with an 
unprecedented resolution in tissue heterogeneity (Klein & Treutlein, 2019) and gain insight on 
transcriptomic dynamic in a time scale of hours (La Manno et al., 2018).  Besides, people can 
also study cell lineage construction with single-cell RNA-seq data, enabling better understanding 
of cellular differentiation and tissue development. Nowadays, there are in total of more than 500 
single-cell transcriptomics studies available (Svensson, da Veiga Beltrame, & Pachter, 2019) 
(Figure 1.6). In the effort to better utilize so many data sets, large consortium projects have been 
launched to integrate them or generate single-cell data sets in a standard way. For example, The 
Human Cell Atlas portal aims to provide uniformly processed single-cell genomics data from all 
of the human body (Regev et al., 2017). Allen Brain Atlas collects functional genomic data of 
Figure 1.6 Single-cell transcriptomics studies over time. The lower panel stratified studies by 
different single-cell techniques. Single-cell studies are explosively increasing in recent years. 
The figures are adapted from Svensson, da Veiga Beltrame, & Pachter, 2019. 
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brains in human and mouse through a wide range of developmental stages to facilitate 
neuroscience studies (Miller et al., 2014).  
 Autism spectrum disorder (ASD) is a neurodevelopmental disorder mostly with very 
early onsets. With rapidly dynamic expression profiles in human fetal brain, we can hypothesize 
that autism risk genes affect specific neuronal cells or pathways during neuron differentiation 
and development. Gene expression level may provide a molecular basis for the pathogenic effect 
of dosage-sensitive risk genes. Learning from autism risk genes’ expression pattern in fetal 
brains not only helps us identify implicated cell types and disease etiology, but also discover 
novel genetic risk in autism. In Chapter 3, we will discuss in detail how we use single-cell 
expression patterns of known autism risk genes to predict novel risk genes and infer affected 






Chapter 2: Distinct Epigenomic Patterns Are Associated with 






Haploinsufficiency (HIS) due to hemizygous deletions or heterozygous likely-gene-
disrupting (LGD) variants plays a central role in the pathogenesis of various diseases. Recent 
large-scale exome and genome sequencing studies of developmental disorders, including autism, 
intellectual disability, developmental delay, and congenital heart disease (De Rubeis et al., 2014; 
Deciphering Developmental Disorders, 2015; Hamdan et al., 2014; Jason Homsy et al., 2015; 
Iossifov et al., 2014), have estimated that de novo LGD mutations explain the cause of a 
significant portion of patients with these developmental disorders, and the enrichment rate of de 
novo LGD variants indicates about half of these variants are associated with disease risk. 
However, relatively few genes have multiple LGD variants (“recurrence”) in a cohort (De Rubeis 
et al.; Iossifov et al.; McRae et al.), lacking of which provides insufficient statistical evidence to 
distinguish individual risk genes from the ones with random mutations (X. He et al.). On the 
other hand, most of the enrichment of LGD variants can be explained by HIS genes (McRae et 
al.). Therefore, a comprehensive catalog of HIS genes can greatly help interpreting and 
prioritizing mutations in genetic studies. 
 Currently, there are two main approaches of predicting HIS genes based on high-
throughput data. Huang et al. uses a combination of genetic, transcriptional and protein-protein 
interaction features from various sources to estimate haploinsufficient probabilities for 12,443 
genes (Huang, Lee, Marcotte, & Hurles, 2010). Using similar input information, Steinberg et al. 
generated the probabilities for more (over 19,700) human genes by a Support Vector Machine 
(SVM) model (Steinberg, Honti, Meader, & Webber, 2015). The other approach is based on 
mutation intolerance (Cassa et al.; Lek et al., 2016; Petrovski, Wang, Heinzen, Allen, & 
Goldstein, 2013) in populations that do not have early onset developmental disorders. Lek et al 
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2016 (Lek et al.) estimated each gene’s probability of haploinsufficiency (pLI: Probability of 
being Loss-of-function Intolerant) based on the depletion of rare LGD variants in over 60,000 
exome sequencing samples. Although effective, ExAC pLI is biased towards genes with longer 
transcripts or higher background mutation rates, since the statistical power of assessing the 
significance depends on a relatively large expected number of rare LGD variants from 
background mutations. 
 We sought to predict HIS using epigenomic data that are orthogonal to genetic variants 
and generally independent of gene size. Our method is motivated by recent studies indicating 
that specific epigenomic patterns are associated with genes that are likely haploinsufficient. 
Specifically, genes with increased breadth of H3K4me3, typically associated with actively 
transcribing promoters, are enriched with tumor suppressor genes (K. Chen et al., 2015b), which 
are predominantly haploinsufficient based on somatic mutation patterns (Davoli et al., 2013). 
Another study reported H3K4me3 breadth regulates transcriptional precision (Benayoun et al., 
2014), which is critical for dosage sensitivity. These observations led us to hypothesize that 
haploinsufficient genes are tightly regulated by a combination of transcription factors and 
epigenomic modifications to achieve spatiotemporal precision of gene expression, and such 
regulation can be detected by distinct patterns of epigenomic marks in relevant tissues and cell 
types. Based on this model, we developed a Random Forest–based method (“Episcore”) using 
epigenomic data from the Epigenomic Roadmap (Roadmap Epigenomics et al., 2015) and 
ENCODE Projects (Consortium et al., 2012) as input features and a few hundreds of curated HIS 
genes as positive training data. To assess the performance of prioritizing candidate risk variants 
in real-world genetic studies, we used large data sets of de novo mutations from recent studies of 
birth defects and neurodevelopmental disorders and showed that Episcore had better 
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performance than existing methods. Additionally, Episcore is less biased by gene length or 
background mutation rate and complementary to mutation-based metrics in HIS-based gene 
prioritization. Our analysis indicates that epigenomic features in stem cells, brain tissues, and 
fetal tissues contribute more to Episcore than others. 
 
2.2 Results 
2.2.1 Haploinsufficient (HIS) and Haplosufficient (HS) genes show distinct distributions of 
epigenomic features 
To examine the correlation of gene haploinsufficiency and epigenomic patterns, we 
analyzed ChIP-seq data from Roadmap and ENCODE projects, including active (H3K4me3, 
H3K9ac, and H2A.Z) and repressive (H3K27me3) promoter modifications, and marks associated 
with enhancers (H3K4me1, H3K27ac, DNase I hypersensitivity sites). We used the width of 
called ChIP-seq peaks for promoter features and counted the interacting number of promoters 
and enhancers within pre-defined topologically-associated domains (TADs) for enhancer 
features. As each histone modification is characterized in multiple cell types, we refer to the 
combination of an epigenomic modification and a cell type as one epigenomic feature.  
Figure 2.1A shows the correlation among epigenomic features, and the correlation of epigenomic 
features and ExAC pLI score. As expected, active promoter or enhancer marks are highly 
correlated with each other and with ExAC pLI score, and they are anti-correlated with repressor 
marks in general. The repressor marks from stem cells or fetal tissues have positive correlations 
with active marks and ExAC pLI scores, suggesting many genes with bivalent marks in stem 





Figure 2.1 Epigenomic profiles are associated with gene haploinsufficiency. (A) Heatmap showing 
Spearman correlation between epigenomic features. Three groups of epigenomic features are included: 
active promoter, repressive promoter and enhancer features. Epigenomic features inside each group 
strongly correlate with each other. Different feature types, including various histone modifications, 
histone variant, and DNase I hypersensitivity sites, are color-coded. Above the heatmap, a bar denoting 
Spearman correction between epigenomic features and pLI shows many epigenomic features relate to HIS 
with varying degree. Data from stem cells or fetal tissues are also marked by color lines. (B-C) Known 
HIS and HS genes have different distributions of peak length of promoter features (B, H3K4me3; C, 
H3K27me3). For each gene, peak length was averaged across tissues. (D) HIS and HS genes have 
different distributions of number of interacting enhancers inferred by Epitensor. For each gene, the 




To further investigate the association of haploinsufficiency and patterns of epigenomic 
modifications, we compiled a list of 287 known HIS genes (Supplementary Table 2.1) involved 
in a wide range of human diseases (Supplementary Table 2.2) from a recent study (Dang, 
Kassahn, Marcos, & Ragan, 2008; Huang et al., 2010) and human-curated ClinGen dosage 
sensitivity map. We also collected a list of 717 HS genes, of which one copy of each gene had 
been deleted in two or more subjects based on a CNV study in 2,026 healthy individuals (Shaikh 
et al., 2009). For promoter features, HIS and HS genes clearly have distinct distributions of peak 
length (Figure 2.1B-D). HIS genes on average have wider peaks of both the active marker 
H3K4me3 (Figure 2.1B) and the repressive marker H3K27me3 (Figure 2.1C), suggesting the 
difference between HIS and HS genes is not only on the level of expression but also on distinct 
mechanisms of regulation. Furthermore, other epigenomic modifications associated with active 
promoters, including H2A.Z and H3K9ac, also display wider peaks upstream of HIS genes 
(Figure 2.2 A and B). In addition, HIS and HS genes also differ in the number of interacting 
enhancers. We adopted a recently published method EpiTensor (Zhu et al., 2016), which 
decomposes a 3D tensor representation of histone modifications, DNase-Seq, and RNA-Seq data 
to find associations between distant genomic regions. When restricted to pre-defined 
topologically-associated domains (TADs), associated regions identified by EpiTensor correspond 
well to enhancer-promoter interactions found by Hi-C20. EpiTensor revealed that HIS genes have 
a median of 9 interacting enhancers, while HS genes have a median of 0 (p < 10-4, permutation 
test, Figure 2.2C).  When averaged across tissues, HIS genes shift towards a larger number of 
mean interacting enhancers, as compared to HS genes (Figure 2.1D), supporting the notion that 








Figure 2.2 The disparity of HIS and HS genes in the distribution of epigenetic 
features. (A-B) HIS and HS genes have different distributions of peak length from 
promoter features (A, H3K9ac; B, H2A.Z). (C) HIS genes have larger numbers of 
interacting enhancers than HS genes. When interacting enhancers were measured as the 
number of peaks in +/- 20kb of TSS (C, the left 3 panels), little difference between HIS 
and HS genes were observed. When interacting enhancers were inferred by EpiTensor (C, 
the rightmost panel), there is significant difference between HIS and HS genes (p < 10-4, 
permutation test of difference between medians). 
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Among these 287 known HIS genes, 129 genes (45%) have pLI smaller than 0.9 or 
missing value. Some of these genes are well-known disease risk genes under dominant genetic 
models, such as TGFB1(Kinoshita et al., 2000), RUNX1(Taketani et al., 2002), SOX2(Fantes et 
al., 2003), SUMO1(Alkuraya et al., 2006), NKX2-5(Benson et al., 1999), EYA4(Wayne et al., 
2001), CAV1(Cao, Alston, Ruschman, & Hegele, 2008), PAX2(Sanyanusin et al., 1995), 
GATA6(Kodo et al., 2009), ZIC2(Brown et al., 1998), and WT1(Hastie, 1992). These known HIS 
genes with pLI < 0.9 have significantly smaller number of expected loss of function variants(Lek 
et al., 2016) than an average gene (Figure 2.3A), and intermediate selection coefficient (Shet) 
(Cassa et al., 2017) (Figure 2.3B), pointing to two particular areas (genes that are either short or 
under intermediate negative selection) in which HIS prediction can be improved.  
Figure 2.3 Property of mutation intolerance and selection of known haploinsufficient genes used in 
training. The known genes are divided into two groups based on ExAC pLI scores: above (red) and below (blue) 
0.9.   (A) The number of expected loss of function (exp_LoF)(Lek et al., 2016) distribution of genes with pLI 
>0.9 or pLI<0.9. The exp_LoF value is proportional to background mutation rate, which in turn is largely 
determined by transcript size. Known HIS genes with pLI < 0.9 have significantly smaller exp_LoF than an 
average gene, and the ones with pLI > 0.9 have much larger exp_LoF.  (B) The Shet (average select coefficient of 
heterozygous loss of function variants in a gene) distribution of genes with pLI>0.9 or pLI<0.9. Shet values. 
Known HIS genes with pLI < 0.9 have intermediate Shet: larger than than an average gene but smaller than the 







2.2.2 Predicting haploinsufficiency with epigenomic features 
To leverage the strong association between epigenomic patterns and gene 
haploinsufficiency, we developed a computational method to predict haploinsufficiency using 
Random Forest (Figure 2.4A) and other supervised learning models (Figure 2.5 A and B). The 
input features included peak length of four promoter marks (H3K4me3, H3K9ac, H2A.Z and 
H3K27me3) and the number of EpiTensor-inferred interacting enhancers in various tissues. 
Performance evaluation by 10-fold cross validation and AUC (Area Under Curve) in ROC 
(Receiver Operating Characteristic) curves showed that all of these methods achieved high AUC 
values of 0.86~0.88 (Figure 2.4B and Figure 2.5 A and B). As Random Forest performs the best, 
Figure 2.4 A Random Forest model to predict haploinsufficiency. (A) A flowchart of the method. 
(B) ROC curve from 10-fold cross-validation. The red curve is the average of 100 randomized cross-
validation runs, with error bar showing standard deviation. The mean and median AUC of the 100 
runs are 0.88 and 0.89, respectively.  
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results from Random Forest are chosen as final metrics measuring the probability of being 
haploinsufficient, termed “Episcore” (Supplementary Table 2.3). Despite completely different 
input data are used, Episcore and ExAC pLI score displayed overall concordance. The 
distribution of pLI is generally bi-modal, with modes at 1 and 0 (Lek et al.). The genes with 
Episocre >0.6 are much more likely to have pLI values close to 1 than genes with Episocre < 0.4, 
and the opposite trend at pLI close to 0 (Figure 2.5C). Among 3463 genes with Episcore > 0.6, 
1518 have pLI scores < 0.5. Some of these genes have been implicated in human diseases under 
a dominant model, such as HEY2(Reamon-Buettner & Borlak, 2006), ASF1A(Giannakou et al., 
2017) and HAND2(Sun et al., 2016) (Supplementary Table 2.4). Similarly to the ones with low 
pLI values in the positive training set, these genes have lower background mutation rate (which 
is primarily determined by transcript size) than the ones with large pLI values (Figure 2.5D), and 





2.2.3 Episcore better prioritizes of de novo LGD variants in developmental disorders 
 A major goal of predicting haploinsufficiency is to facilitate prioritization of variants 
identified in genetic studies of developmental disorders. We compared Episcore with pLI scores 
from ExAC (Lek et al., 2016), Shet values (selection coefficient of heterozygous LGD variants) 
(Cassa et al., 2017), and ranks of mouse heart expression level (Zaidi et al., 2013), using de novo 
LGD variants identified in a recently published whole exome sequencing study DDD 
(Deciphering Developmental Disorders consortium) of 1,365 trio families with congenital heart 
disease (CHD) (Sifrim et al., 2016). LGD variants include frameshift, nonsense and canonical 
splice site mutations. We only included genes with all 4 metrics for comparison, although we 
note Episcore (19,430 genes) made predictions for more genes than pLI (18,225 genes), Shet 
(17,200 genes) and ranks of mouse heart expression level (17,624 genes, due to loss in 
orthologue matching). Different predictions are compared by the enrichment rate  
of variants. For the same number of top-ranked genes by each metric, we calculated the number 
of LGD variants located in these genes and estimated the number of LGD variants based on  
background mutation rate (Samocha et al., 2014). Across a wide range of top-ranked genes, 
Episcore showed larger enrichment than ExAC pLI, Shet, or heart expression level (Figure 2.6A 
and Figure 2.7A). We also applied the same approach to de novo synonymous variants identified 
Figure 2.5 Performance of various machine learning approaches and concordance of Episcore with 
pLI. (A-B) ROC curve of 10-fold cross-validation from applying SVM (A) or SVM with Lasso feature 
selection (B) to the same epigenetic data as used in the Random Forest model. The red curve is the 
average of 100 randomized cross-validation runs, with error bar showing standard deviation. (C) pLI 
distribution of Episcore < 0.4 and Episcore >0.6 genes. The genes with Episcore > 0.6 are much more 
likely to have pLI values close to 1 than the genes with Episcore < 0.4, and less likely to have pLI values 
close to 0 than the genes with Episcore <0.4. (D) The distribution of background LGD mutation rate 
(log10). The genes with Episcore>0.6 and pLI < 0.5 have similar background mutation rate as an average 
gene, whereas the genes with pLI > 0.5 have higher background mutation rate, and the ones with pLI > 
0.9 have even higher background rate. (E) The distribution of Shet: genes with Episcore >0.6 and pLI < 
0.5 have intermediate Shet values that are larger than an average gene and smaller than the genes with 






in the CHD dataset and observed no enrichment (Figure 2.7B). Additionally, we compared these 
predictions by precision-recall-like curve (PR-like) based on enrichment. Since the total number 
of positive variants (true disease-causing variants) is unknown, we used estimated number of 
“true positives” instead of “true positive rate (recall)” in this comparison. For top-ranked genes 
from each method, the number of true positives were estimated by subtracting expected number 
of LGD variants based on background mutation rate from the observed in these genes. We 
measured precision by dividing the estimated number of true positives by the total number of 
observed LGD variants in these genes. Across a wide range of precision, Episcore consistently 
showed superior recall compared to pLI, Shet and heart expression level (Figure 2.6B) and to 
earlier methods based on combination of genetic and protein interaction network data (Huang et 
al., 2010; Steinberg et al., 2015) (Figure 2.7C and D). The performance advantage over other 





Figure 2.6 Assessment of the performance of Episcore in variant prioritization using de novo mutation 
data. (A-B) Comparison of Episcore, pLI, Shet and heart expression level (HE) in variant prioritization using 
CHD exome sequencing data. In (A), burden refers to the ratio between the number of de novo LGD variants 
observed in top genes ranked by each metric and the number of expected de novo LGD variants due to 
background mutation. Episcore has higher enrichment in top 1000-2500 genes and similar enrichment 
afterwards. The grey dash line indicates the burden of de novo LGD variants in all genes. (B) Precision-recall-
like curves. True positive is the difference between the observed and expected de novo LGD variants. 
Precision is calculated by dividing the number of true positives by the number of observed de novo LGD 
variants. The blue curve for Episcore shifts upright than pLI and Shet, showing Episcore has better recall with 
precision and vice versa. (C-D) Episcore has less bias towards genes with longer CDS length (C) or larger 
background mutation rate (D) than pLI. Grey histogram in the background represents CDS length or mutation 
rate of all genes in the genome. The blue curve for pLI shifts right, while the curves for Episcore and HE are 
similar to the distribution of all genes and known HIS genes. (E-F) A combination of Episcore and pLI, the 
meta-score, has better performance in variant prioritization when benchmarked using DDD exome sequencing 
data. Meta-score is the output from a logistic regression model, using Episcore and pLI as input. Enrichment, 







Figure 2.7 Using empirical data to benchmark the performance of Episcore in variant 
prioritization. (A) Comparison of enrichment burden between Episcore and pLI, shown with 95% 
confidence intervals calculated based on Poisson distribution. (B) Enrichment of CHD silent de novo 
variants is close to 1 regardless of Episcore rank. (C-D) Comparing Episcore to prediction of 
haploinsufficient genes from two previous studies based on protein interaction networks (Huang et al., 
2010; Steinberg et al., 2015), using CHD exome sequencing data. The grey dash line indicates the burden 
of de novo LGD variants acorss the genome. (E-F) Comparison of Episcore, pLI, Shet and heart expression 
level excluding known HIS genes used in training. Episcore achieves better performance than mutation 
intolerance based metrics. (G) The distribution of Shet (log10) of genes that have LGD de novo mutations 
in DDD ID and CHD cases. Overall a larger fraction of genes with mutations in DDD ID cases have high 
Shet values, indicating the disease-causing genes are under more severe selection on average.  
  
We obtained a second CHD WES cohort of 2,645 parent-offspring trios from the 
Pediatric Cardiac Genomics Consortium (PCGC) (Jin et al., 2017) to emulate a replication 
design. We used the larger data (PCGC CHD) as discovery and the DDD data as replication. We 
found that the genes with a single LGD variant in PCGC data and “replicated” with at least one 
LGD variant in the DDD data have much higher Episcore, than the genes with a singleton LGD 
in PCGC data or genes with LGD variants in controls (unaffected siblings in Simons Simplex 
Collection autism study (Krumm et al., 2015))(Figure 2.8). 
 
2.2.4 Episcore provides complementary information to mutation intolerance metrics 
Haploinsufficiency predicted by mutation intolerance in a general population (such as 
ExAC pLI metric) is intrinsically biased towards genes with longer CDS (coding sequence) 
lengths or higher background mutation rates. Figure 2.6C and D show the distribution of genes 
with pLI scores > 0.9 shifts towards longer CDS length or higher background mutation rate, as 
 compared to the distribution of known HIS disease risk genes, while top 20% genes ranked by  
Episcore have similar distribution to known HIS disease risk genes or genes with expression 
level ranked in top 20% in developing heart (Zaidi et al.).   
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Since Episcore and pLI use distinct types of input data, a combination of these two scores 
might achieve better performance. We obtained de novo mutation data of 4,293 trio families 
affected by developmental disorders, mostly with intellectual disabilities (DDD ID), from a 
recent study(McRae et al., 2016). Genes with de novo LGD mutations in DDD ID cases are 
notably under more severe selection than the ones in CHD (Figure 2.7G). We used a logistic 
regression to integrate Episcore and pLI in this data set. Specifically, we used a total of 45 genes 
with de novo LGD variants in 3 or more probands as positives, and randomly sampled 45 genes 
from genes with no observed de novo LGD variant as negatives to estimate coefficients in the 
logistic model.  Both Episcore and pLI have significant coefficients (P < 10-3), supporting these 
two methods convey complementary information. We found that the resulting meta-score 
Figure 2.8 Episcore distribution of genes with de novo LGD variants in DDD CHD cohort and 
PCGC CHD cohort. Data in an earlier version of PCGC CHD cohort is depleted from DDD CHD 
data due to duplication. The distribution of genes with single LGD variant in PCGC cohort and at 
least one LGD or D-mis variant in DDD CHD cohort are close to the distribution of genes with 
multiple LGD variants in PCGC cohort, suggesting that Episcore facilitates discovery of de novo risk 
genes with only one LGD variant. For comparison, genes with de novo single LGD variant detected 
from an SSC control cohort have lower Episcore distribution. 
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achieved overall better precision and true positives than Episcore or pLI alone (Figure 2.6 E and 
F), while maintaining similar enrichment burden as good as any method alone in a broad range 
of gene ranks.   
 
2.2.5 Brain tissues, fetal tissues, and stem cells highly associate with the predicted 
haploinsufficiency 
To evaluate the association of each epigenomic feature to haploinsufficiency, we 
calculated Spearman correlation coefficients between each feature and Episcore. These 
correlation coefficients were analyzed in two ways. We first grouped them based on the 
molecular entities they represent, such that the same epigenomic modification from different 
tissues would be in one group. Each of the 5 resulting categories has distinct distributions of 
Spearman correlation coefficients, suggesting different contributions to Episcore (Figure 2.9A). 
Except for the repressive mark H3K27me3, most of them have larger correlation coefficients 
than gene expression values, suggesting these features and the model do not merely reflect 
expression abundance but also epigenomic regulation specific to HIS genes. Measured by mean 
decrease of Gini index, these groups of features have similar trend in contribution to Episcore 
prediction (Figure 2.10). 
We then grouped correlation coefficients based on tissue and cell types, converted 
correlation coefficient of each epigenomic modification to a Z-score using the mean and standard 
deviation across the tissue or cell type, and finally averaged the Z-score of all epigenomic 
modification for each tissue or cell type. The averaged Z-score represents the importance of this 
tissue or cell type to haploinsufficiency prediction. In general, stem cells and neural tissues have 
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large average Z-scores (Figure 2.9B). Interestingly, for tissues in the same category, fetal tissues 






Finally, to illustrate the contribution of different tissues to HIS, we examined in detail the 
histone modifications around TSS of several known HIS genes. Figure 2.9C show RBFOX2 and 
CWC22. RBFOX2 is a CHD risk gene recently discovered through de novo LGD variants (Jason 
Homsy et al.), and it has expansive H3K4me3 and H3K9ac peaks in stem/fetal cells and heart 
and brain tissues, but not in blood cells. Consistently, it has a reverse pattern in H3K27me3, 
extensive in blood cells but limited in other tissues. On the contrary, CWC22, a known house-
keeping gene, shows consistent but narrow peaks of active marks across tissues. 
Figure 2.9 Contribution of epigenomic features to Episcore prediction. (A) Spearman correlation 
between epigenomic feature and Episcore. Features used in the Random Forest model, including H2A.Z, 
H3K27me3, H3K4me3, H3K9ac and the number of interacting enhancers, all have positive correlation 
with Episcore. Spearman correlation coefficients between gene expression level, measured in RPKM 
(reads per kilobase per million reads), and Episcore were also plotted for comparison. (B) The importance 
of each tissue in generating Episcore is measured by average Z-score, which is converted from Spearman 
correlation coefficients between epigenomic feature and Episcore. Each dot represents one cell line or 
tissue type indicated by colors. Stem cells and neural and fetal tissues are the most important tissue and 
cell types in Episcore prediction. (C) The epigenomic profile of an example HIS gene, RBFOX2, and a 
house-keeping gene, CWC22. Each small box represents 100bp region around TSS and the shade of the 
color reflects averaged fold change of reads between ChIP-seq library and control samples. RBFOX2 has 
a broad expansion of epigenomic marks while CWC22 is not, and RBFOX2 shows more tissue-specific 





 In this study we showed there is a strong correlation between epigenomics patterns and 
gene haploinsufficiency, and developed a computational method (Episcore) to predict HIS using 
epigenomic features. Episcore had superior yet complementary performance in prioritization of 
de novo LGD variants in congenital heart disease and neurodevelopmental disorders, compared 
to mutation intolerance metrics such as ExAC pLI (Lek et al.).    
Figure 2.10 The importance (mean decrease of Gini index) of each feature to Episcore prediction.  
We obtained the importance values from the randomForest R package. Features are grouped by 
epigenomic molecular entities. For each group, we summarize the distribution of importance metric 
across cell and tissue types. Active promoter and enhancer features (H3K4me3, H3K9ac, H2A.Z, 
Enhancer) show higher importance than repressive promoter features (H3K27me3). 
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 Existing HIS prediction methods based on intolerance of mutations have limited 
statistical power in genes with small transcript size or under less severe negative selection. 
Network-based methods(Huang et al., 2010) are often biased towards well-studied genes 
(Steinberg et al., 2015) and pathways. Epigenomic data have several advantages to address these 
issues: (a) they are orthogonal to genetic mutations, and therefore provide additional information 
that could improve power; (b) they are much less biased by transcript size, and will be most 
helpful to predict HIS of genes with short transcripts; (c) the bias with selection coefficient is a 
reflection of the training data, which empirically is much smaller than mutation intolerance 
metrics; (d) the ability to generate large amount of data without bias towards well-studied genes. 
These advantages contribute to the superior performance of Episcore in prioritizing de novo 
LGD variants from exome sequencing studies.  
There are likely a variety of mechanisms underlining the correlation of epigenomics 
patterns and haploinsufficiency. First, broad H3K4me3 peaks contributed most to Episcore 
prediction of HIS. Broad H3K4me3 peaks are associated with reduced transcriptional noise at 
cell population and single cell levels (Benayoun et al.), which is likely required to maintain 
precise expression levels of HIS genes in specific cell types and developmental stages. Second, a 
previous study found regulatory complexity is required to achieve cell-type specific expression 
patterns of the lineage-defining genes in hematopoietic differentiation (Gonzalez, Setty, & 
Leslie). Consistently, we found the number of enhancers interacting with the promotor of a gene 
is highly correlated with predicted HIS score. Third, many HIS genes are regulators that define 
cell lineages during differentiation. Bivalent chromatin domains in embryonic stem cells, in 
which both active marker H3K4me3 and repressor marker H3K27me3 are present, are generally 
associated with lineage control genes (Vastenhouw & Schier). We observed that H3K27me3 are 
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positively correlated with H3K4me3 in stem cells, and both are correlated with mutation 
intolerance (Figure 2.1A and C) and Episcore (Figure 2.9A). Finally, we found epigenomic 
features from stem cells and fetal tissues contribute most to prediction, highlighting the 
importance of developmental role in determining gene haploinsufficiency. 
Our data suggests Episcore is generally better for prioritizing genes with a broader range 
of selection coefficient or genes with smaller transcript size, whereas pLI performs better for 
genes under most severe negative selection. Episcore is currently limited by availability and 
resolution of epigenomic data, especially cell-type specific data from complex tissues or organs 
such as the brain, and data at various developmental stages. Complex developmental disorders, 
such as autism, involve a large number of cell types during a broad range of developmental 
stages. It is critical to generate and integrate more fine-grained epigenomic data from cells of 
specific types at specific time points in order to improve genetic discoveries in studies of such 
diseases. We expect such data sets will become available in near future from ongoing projects 
(Dekker et al.; Psych et al.; Stunnenberg, International Human Epigenome, & Hirst, 2016), and 
will enable us to improve prediction of HIS and facilitate novel discoveries in genetic studies. 
 
2.4 Material and methods 
2.4.1 Collection and Preprocessing of Training Genes 
In this study, we used Ensembl release 75 for gene annotation and TSS (transcription 
start site) locations. All genomic coordinates are based on hg19 human genome assembly. Any 
non-hg19 coordinates were lifted over to hg19 using UCSC LiftOver tool ( 
https://genome.ucsc.edu/cgi-bin/hgLiftOver ). Conversion of gene symbols to Ensembl IDs were 
based on annotation tables downloaded from Ensembl BioMart. 
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Positive training set data (curated haploinsufficient genes) were collected from these two 
sources: (1) haploinsufficent training genes used in previous studies (Dang et al., 2008; Huang et 
al., 2010)  and (2) genes with haploinsufficient score of 3 in ClinGen Dosage Sensitivity Map ( 
http://www.ncbi.nlm.nih.gov/projects/dbvar/clingen/ ). For the negative training set (curated 
haplosufficient genes), we used genes deleted in two or more healthy people, based on CNVs 
detected in 2,026 normal individuals (Shaikh et al., 2009). Only genes with half or more of its 
length covered by any deletion were considered “deleted” in an individual.  
 The raw training set may have some false positives and false negatives, as it contained 
results from automated literature mining that is known to give noisy output. To optimize the 
performance, we did the following pruning of the raw training set: (1) we only kept protein-
coding genes in autosomes, as non-protein-coding genes or genes on sex chromosomes may be 
under different mechanism of epigenomic regulation; (2) from the positive training set, we 
removed genes with sufficient contradictory evidence (ExAC pLI ≤ 0.1 and expected loss-of-
function variants > 10 (Lek et al.)); and (3) from the negative training set, we removed genes 
with sufficient contradictory evidence (pLI  ≥  0.9 and expected loss-of-function variants > 10). 
After pruning, the positive training set has 287 genes and the negative training set has 717 genes. 
The full list of training genes is available in Supplementary Table 2.1. 
 
2.4.2 Preprocessing of Epigenomic Feature Data 
The uniformly processed peak calling results of Roadmap and ENCODE projects were 
downloaded from http://egg2.wustl.edu/roadmap/web_portal/processed_data.html. For promoter 
features (H2A.Z, H3K27me3, H3K4me3, and H3K9ac), “GappedPeaks” were used to allow for 
broad domains of ChIP-seq signal. The assignment of a GapppedPeak to a gene follows these 
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steps in order: (1) for each gene, only TSS of Ensembl canonical transcripts were used. (2) 
assigned a GappedPeak to a TSS if the GappedPeak overlaps with the upstream 5kb to 
downstream 1kb region around the TSS. This definition of basal cis-regulatory region around 
promoter follows GREAT tool (McLean et al., 2010). Assigning one GappedPeak to multiple 
TSS was allowed. (3) For TSS having more than 1 GappedPeak assigned, kept the closest one. 
(4) For genes with multiple TSS and hence multiple assigned GappedPeaks, kept the longest 
GappedPeak. After these four steps, if one gene had been associated with a GappedPeak, then we 
used the width of the peak as an epigenomic feature in the following machine learning models. If 
a gene had no associated GappedPeak, then the peak width is 0. 
To calculate the number of interacting enhancers of a gene, we used two approaches. In a 
naïve approach, we counted peaks of ChIP-seq signals that are associated with enhancers. The 
ChIP-seq signals we used include H3K4me1, H3K27ac and DNase I hypersensitivity site, and 
each ChIP signal was counted and recorded separately. We used “NarrowPeak” instead of 
“GappedPeak” in the counting to better estimate the number of interacting enhancers, as 
enhancer regions are not long and GappedPeak has the risk of merging nearby ChIP-seq signals. 
For each gene, we counted peaks in (a) the surrounding TAD (Topologically Associated 
Domain), based on TADs reported in (Dixon et al., 2012); or (b) +/- 20kb of each TSS (Only 
TSSs of Ensembl canonical transcripts were used. For genes with multiple TSS and thus several 
numbers of interacting enhancers, we kept the largest one). In a more advanced approach, we 
adapted EpiTensor (Zhu et al., 2016) to infer gene-enhancer relationship. We made a few 
changes when using EpiTensor: (a) we used normalized coverage of ChIP-seq signal instead of 
raw coverage in Zhu et al. 2016 (Zhu et al.);  (b) we used the coverage of H3K27ac, H3K27me3, 
H3K36me3, H3K4me1, H3K4me3, H3K9me3, DNase I and RNA-seq as input for EpiTensor to 
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balance between more input data types and more cell types included, as not every cell type has 
all these histone modifications characterized. The number of data types included are fewer than 
the ones used in Zhu et al. 2016 (Zhu et al.), but it could still achieve desirable performance 
(personal communications); (c) we used enhancer annotation from 15-state chromHMM ( 
http://egg2.wustl.edu/roadmap/web_portal/chr_state_learning.html#core_15state ), while the 
original EpiTensor paper (Zhu et al.) used results of an earlier version. Based on the output of 
EpiTensor, which predicts enhancer-promoter pairs, we counted the number of interacting 
enhancers for each gene in various tissues. 
Finally, the results of peak width and number of interacting enhancers were consolidated 
into a matrix, with each row being a gene and each column representing a combination of a 
tissue and a data type, e.g. “H3K4me3 peak width in fetal heart”. One combination of a tissue 
and a data type was referred to as one epigenomic feature. This matrix was used as input for 
machine learning models described in the following section. 
 
2.4.3 Machine learning approaches to predict haploinsufficiency 
We applied several machine learning approaches, including Random Forest, Support 
Vector Machine (SVM) and SVM with LASSO feature selection. Random Forest was 
implemented using R package “randomForest”. SVM was implemented using R package 
“e1071”. LASSO was implemented using R package “glmnet”, with alpha value equal to 1. For 
each machine learning method, we assessed the performance based on 100 runs of 10-fold cross-
validation. In each run, 10% of the training genes were randomly selected and left out to form a 
test set for validation. The remaining data were used to train the model, after which the test set 
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was used to calculate model sensitivity and specificity. We used R package “ROCR” to make a 
ROC curve based on the 100 runs and calculated AUC values. 
Finally, we used all training genes used to train the model, and then estimate the 
probabilities of being positive (i.e. probabilities of being HIS) for all genes. The whole process 
was repeated 30 times and we took the arithmetic mean of the 30 sets of probabilities as the final 
results. 
 
2.4.4 Comparing Episcore and other metrics in variant prioritization 
We used two approaches to compare Episcore and other metrics in variant prioritization, 
based on “enrichment of de novo LGD variants”, estimated “number of true-positives” and 
“precision”. The formula to calculate these three statistics are as follows.  
 For any gene i, the number of expected de novo LGD variants in each gene, Ei, was 
calculated as: 
     Ei = 𝟐𝟐 ×  𝑵𝑵 × ri 
where N is the number of cases in the sequencing cohort and ri is gene-specific LGD mutation 
rate. LGD variants include nonsense, frameshift and canonical splice site mutations. The 
background mutation rate per gene of each mutation type was obtained from Samocha et al. 2014 
(Samocha et al.). For each gene, ri  is the sum of background mutation rate of nonsense, 
frameshift and canonical splice site mutations. 
 For a set of genes, the enrichment of de novo LGD variants, D, was calculated as: 
      𝑫𝑫 =  𝑴𝑴
∑ 𝑬𝑬𝒊𝒊𝒊𝒊
 
where M is the total number of observed de novo LGD variants in this gene set.  In this study, we 
used results from two whole exome sequencing studies on congenital heart disease (Jason 
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Homsy et al., 2015; Sifrim et al., 2016) and another whole exome sequencing study on various 
developmental disorders (McRae et al., 2016).  
           For any gene set, the number of true positives, TP, was calculated as: 
             𝑻𝑻𝑻𝑻 = 𝑴𝑴 −  ∑ 𝑬𝑬𝒊𝒊𝒊𝒊  
           For any gene set, the precision (positive predictive value), PPV, was calculated as: 
                PPV= M - ∑ Eii
M
 
For each metric (Episcore, pLI, etc.), a series of top-ranked genes were selected, such as 
top 500 genes, top 2000 genes, etc. In the first approach, enrichment of de novo LGD variants, 
D, was calculated for any set of top-ranked genes, and then enrichment values were plotted and 
compared, as shown in Figure 2.6A.  In the second approach, the number of true positives, TP, 
and the precision (true discovery rate), PPV, were calculated for any set of top-ranked genes. TP 
and PPV were plotted and compared, as shown in Figure 2.6B. If the number of all true positives 
(N) in a study is known, we can calculate recall as R = TP/N. Although N is generally unknown, 
it is a constant; therefore, TP is proportional to R. In this study, we use TP as a proxy of recall.      
To examine the utility of Episcore in prioritizing genes with only one LGD mutation, we 
utilized two independent Congenital Heart Disease (CHD) cohorts: DDD (Deciphering 
Developmental Disorders consortium) CHD (Sifrim et al., 2016) and PCGC (Pediatric Cardiac 
Genomics Consortium) CHD (Jin et al., 2017). Both these studies included trios from an earlier 
CHD study (Zaidi et al., 2013) to increase detection power. To avoid duplication, we removed 




2.4.5 Epigenomic features critical in the prediction 
We calculated a Spearman correlation coefficient between each epigenomic feature and 
Episcore. One epigenomic feature here corresponds to a data type (like H3K4me3 peak width) in 
certain tissue/cell type (e.g. fetal heart). To examine which data types are more important, we 
plotted these Spearman correlation coefficients by data type, e.g. correlation coefficients from 
H3K4me3 peak width were plotted in one section. To examine what tissue/cell types are more 
important, we calculated averaged z-score for each tissue/cell type. The average z-score is 
calculated following these two steps: (1) we converted every Spearman correlation coefficient to 
a Z-score using mean and standard deviation specific to each data type and (2) for each 













Autism spectrum disorder (autism) is a phenotypically heterogeneous developmental 
disorder, affecting 1 in 59 children in the United States (Baio et al., 2018).  Earlier studies have 
shown a strong genetic basis for autism with up to 90% concordance between monozygotic twins 
(Bailey et al., 1995; Rosenberg et al., 2009) and 10-fold higher chance for younger sibling to be 
diagnosed with autism if there is an older affected sibling (Constantino, Zhang, Frazier, 
Abbacchi, & Law, 2010; Ronemus, Iossifov, Levy, & Wigler, 2014). Simulations estimate one 
thousand autism risk genes with large effect (Iossifov et al., 2014); however, currently only 
about 100 known risk genes (Abrahams et al., 2013) have robust evidence from recent studies 
(De Rubeis et al., 2014; Iossifov et al., 2014; Turner et al., 2016). These known risk genes only 
account for less than 5% of autism cases (Krumm, O'Roak, Shendure, & Eichler, 2014). 
Therefore, it is critically important to identify new risk genes. However, the identification of new 
risk genes based on statistical evidence is limited by lack of power due to sample sizes.  
 A general approach to improve the power for detecting risk genes is to use prior 
knowledge and functional genomic data to predict plausibility of candidate risk genes. Previous 
studies have implemented network-based methods utilizing genotype-phenotype associations 
(Baio et al., 2018; Chang, Gilman, Chiang, Sanders, & Vitkup, 2015; Gilman et al., 2011), 
protein-protein physical interactions (O'Roak et al., 2012), brain-specific functional interactions 
(Krishnan et al., 2016) and gene coexpression networks (Parikshak et al., 2013; Willsey et al., 
2013). We previously developed a semi-supervised method using cell-type specific expression 
profiles from mouse bulk microarray data based on Principle Component Analysis (PCA) (C. 
Zhang & Shen, 2017). One advantage of using cell-type specific expression is the ability to 
jointly infer plausible risk genes and cell types that are correlated with risk plausibility, 
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potentially improving the understanding of the disease mechanism. Our method was limited by 
the lack of spatiotemporal cell-type information from developing brains and the species 
difference between mouse and human. Recent studies have developed machine learning 
approaches to classify autism risk genes with human brain expression data (Brueggeman, 
Koomar, & Michaelson, 2018; Lin, Rajadhyaksha, Potash, & Han, 2018), but are still limited by 
the resolution of data in cell types or developmental stages pertinent to the disease.  
With the motivation to identify new risk genes for autism, here we developed a 
supervised machine learning method based on gradient boosting trees, "A-risk" (Autism risk), 
that can learn known risk genes' expression patterns in single-cell transcriptomics of human fetal 
midbrain and prefrontal cortex, to then predict the plausibility of any gene being an autism risk 
gene. We hypothesize that autism risk genes have distinct spatiotemporal expression signatures 
in developing human brain in neurotypicals. When comparing A-risk to other metrices or 
methods in prioritizing risk variants, we observed better performance of A-risk in prioritizing 
candidate risk variants using de novo variant data of 8838 trios from recent publications(R. Chen 
et al., 2017; Feliciano et al., 2019; Iossifov et al., 2014; Satterstrom et al., 2020; Takata et al., 
2018; Yuen et al., 2017). Furthermore, we showed that A-risk and gene mutation intolerance 
metrics(Lek et al., 2016) can be combined to improve prior estimation in an empirical Bayesian 
model and enables identification of additional novel risk genes. Finally, we investigated the cell 
type specific expression patterns in adult brain of known and novel autism risk genes and found 
that they are highly expressed in deep-layer excitatory neurons in adult human cortex, suggesting 





3.2.1 Single-cell expression pattern is correlated with autism risk  
We obtained two single-cell RNA-seq data sets from human fetal midbrain and prefrontal 
cortex. The midbrain data are mostly from the first trimester (La Manno et al., 2016), while the 
prefrontal cortex data are mostly from the second trimester (Zhong et al., 2018).  Previous 
studies have suggested the role of prefrontal cortex (Amaral, Schumann, & Nordahl, 2008; 
Geschwind, 2011; Rubenstein, 2011; Voineagu et al., 2011) and midbrain dopamine system 
(D'Ardenne et al., 2012; Ott & Nieder, 2019; Ranganath & Jacob, 2016). On average, 2302 and 
4503 genes per cell are detected in the midbrain and the prefrontal cortex data, respectively 
(Figure 3.1). We obtained the cell type labels from original publications, and then define the 
Figure 3.1 Quality of single cell RNA-seq data. The number of log10 based UMIs in each cell 
from the two data sets against the number of genes detected. The detected genes are defined as 
genes with larger or equal to 1 UMI. The midbrain data has more genes detected than the prefrontal 
cortex data given the same number of UMIs. 
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expression level of a gene in a cell type as the fraction of cells with ≥1 UMIs (Unique Molecular 
Identifiers) in the cell type at a certain developmental time point. The feature set of our data is 
the combination of cell types and developmental time points (Supplementary Table 3.1).  
To investigate temporal and cell type specific expression pattern of autism risk genes, we 
collected 88 known autism risk genes from the SFARI (Simons Foundation Autism Research 
Initiative) Gene database (Abrahams et al., 2013) (released version on 08/29/2019, score 1 or 2), 
which are genes strongly implicated in autism based on expert curation from the literature. We 
also obtained 154 genes with at least 1 de novo LGD (likely-gene disrupting) variant in 
unaffected siblings from an exome-sequencing study(Iossifov et al., 2014) (Supplementary Table 
3.2), representing non-risk genes with random de novo mutations. Known risk genes tend to have 
a wide range of average expression level in both data sets, while non-risk genes have lower 
average expression (Figure 3.2A). We performed PCA (Principle Component Analysis) of these 
two groups of genes using expression level from the single cell data sets. The first component 
partially separates known risk genes and non-risk genes (Figure 3.2B). This is consistent with 





Figure 3.2. Different expression pattern of known autism risk genes and random genes in fetal 
midbrain and prefrontal cortex. (A) The expression distribution of known autism risk genes and 
random genes in fetal midbrain and prefrontal cortex. (B) PCA analysis of fraction expression of known 
autism risk genes and random genes. The density plots along axes shows the difference of known risk 




To leverage the temporal and cell type specific expression pattern of known autism risk 
genes, we developed a supervised machine learning method, “A-risk”, to predict plausibility of 
being an autism risk gene for all protein-coding genes (Supplementary Table 3.3). A-risk is 
based on gradient boosting. We train the model using 88 known autism risk genes as positives 
and the 154 non-risk genes as negatives. Figure 3.3A shows the overall workflow of A-risk. 
Figure 3.3 A-risk, a gradient boosting tree model to estimate plausibility of being risk genes of autism 
from single-cell RNA-seq data.  (A) A flowchart of the method. (B) A-risk score distribution. A-risk of all 
genes in the genome are shown in the histogram in gray. The distribution of A-risk of known autism risk genes 
and randomly mutated genes, which are positive and negative training sets in A-risk model respectively, are 
shown as orange and purple density curves. A-risk score 0.4 is where the positives and negatives show 
separation. (C) “Feature importance” derived from the gradient boosting trees model showing cell types from 
both midbrain late first trimester and prefrontal cortex second trimester make substantial contribution to the 
prediction. The y-axis is the relative important of each feature against the max, which is GABAergic neurons 
in midbrain at week 9.  W, week. Gaba, GABAergic neurons. Exc, excitatory neurons. Dopa, Dopaminergic 
neurons. NbGaba, neuroblast GABAergic. Nb, neuroblast. GabaInter, GABAergic interneurons. OMTN, 
oculomotor and trochlear nucleus. 
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Five-fold cross-validation during training achieves an average AUC (Area Under Curve) of ROC 
(Receiver Operating Characteristic) curves at 0.77 (Figure 3.4). A-risk score distribution shows a 
large separation of known risk genes and non-risk genes (Figure 3.3B). We chose A-risk 0.4, 
corresponding to top 2642 ranked genes, as a recommended cutoff for analysis where a binary 
stratification of genes is needed.  
We quantify the contribution of cell types to A-risk prediction by feature importance, a 
score for each feature measuring how valuable it is in constructing the model. The top ranked 
cell types are GABAergic neurons in midbrain at week 9, dopaminergic neurons in midbrain at 
week 10 and prefrontal cortex excitatory neurons at week 12 (Figure 3.3C). Overall, cell types 
from both midbrain late first trimester and prefrontal cortex second trimester made substantial 
contribution to the prediction. The full list of feature importance from the model is available in 
Supplementary Table 3.4. 
Figure 3.4 Training of A-risk: performance in cross-validation and importance of cell types and 
time points to the model. ROC curves of 5-fold cross validation using training data, where the 
training samples are divided as 80% for training and 20% for validation. The blue curve is the average 
of the 5 curves and the grey band in the background marks the interval between the left and right first 
standard deviation.  
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3.2.2 A-risk improves prioritization of de novo variants in autism cases 
To investigate if A-risk can prioritize de novo risk variants detected from exome or 
genome sequencing studies, we compiled de novo likely gene-disrupting (LGD) variants of 8838 
trios from recent published studies (R. Chen et al., 2017; Feliciano et al., 2019; Iossifov et al., 
2014; Satterstrom et al., 2020; Takata et al., 2018; Yuen et al., 2017) (Table 3.1). We calculated 
enrichment rate of LGD de novo variants in a gene set by the observed number of variants 
divided by the expected number estimated from background mutation rate models (Carlson et al., 
2018; Samocha et al., 2014) (Table 3.2). The enrichment rate for all genes excluding known risk 
genes is 1.4, suggesting there are additional risk genes that harbor de novo LGD variants. When 
further selecting genes by A-risk ≥0.4, the enrichment rate reaches 2.1 (p-value=1.3e-32, Poisson 
test), showing that A-risk can increase the signal-to-noise ratio in prioritized candidate risk 
genes.  
  Table 3.1 Summary of publication sources of de novo variants data. 
 
Cohort label Number of unique cases Publication 
ASC 3625 (Satterstrom et al., 2020) 
De Rubies 421 (De Rubeis et al., 2014) 
SSC 2501 (Iossifov et al., 2014) 
SPARK pilot 465 (Feliciano et al., 2019) 
MSSNG 1529 (Yuen et al., 2017) 
JPASD 232 (Takata et al., 2018) 







To further assess the utility of A-risk in prioritizing novel risk genes, we compute 
enrichment and precision-recall like curves and compare with other methods. The precision-
recall like curves compare the utility of each method in prioritizing true risk variants(Carlson et 
al., 2018; Samocha et al., 2014). With each method, we rank all genes. In all genes above a 
certain rank threshold, we estimate the number of detected true risk variants (“positives”) by the 
difference of observed number of variants (“detected positives”) and expected number. The total 
number of true positives is unknown, but it is a constant independent of methods. Therefore, the 
estimated number of true positives is a proxy of recall. The estimated precision is the number of 
detected true positives divided by the total number of detected positives. Besides the de novo 
LGD variants we used for Table 3.1, we included deleterious missense (D-mis) variants defined 
by REVEL score (Ioannidis et al., 2016) ≥0.5 in the following analysis. In addition, all known 
risk genes used in model training are excluded from analysis. We compared A-risk with mouse 
brain bulk expression ranks at E9.5 (J. Homsy et al., 2015), ExAC pLI (Lek et al., 2016), and the 
baseline where the corresponding estimates are calculated in all protein-coding genes (excluding 










Expected  Enrichment 
Rate 
P-value 
All genes (N=18663) 1341 784 1.7 3e-73 
Excluding known risk genes 
(N=18575) 
1114 774 1.4 9e-31 
A-risk≥0.4, excluding known risk 
genes (N=2566) 
313 148 2.1 1e-32 
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ranked genes compared to others and significantly higher than the genome baseline (Figure 
3.5A). At the 2500 top rank, roughly corresponding to A-risk score 0.4, A-risk achieves better 
precision than other metrices and prioritizes almost half of total de novo variants with a relatively 
high precision (0.46), a 64% improvement from the genome-wide baseline (precision=0.28) 
(Figure 3.5B). Furthermore, in non-constrained genes (pLI<0.9), A-risk shows significantly 
higher enrichment and better precision compared to mouse brain expression levels (Figure 3.5C 
and D), indicating A-risk is complementary to pLI with the potential to optimize risk gene 
discovery, especially among non-constraint genes. We also compared A-risk with other recent 
methods aimed to find novel autism risk genes, such as D-score (C. Zhang & Shen, 2017) and 
Krishnan 2016 (Krishnan et al., 2016) (Figure 3.6). A-risk again shows superior performance in 
enrichment, precision and true positives from top 1500 to top 4000 ranks of the three methods 






Figure 3.5 Superior performance of A-risk in prioritization of de novo variants at top 2500 
ranks, especially in non-constraint genes. A-B, comparison of A-risk to mouse brain expression 
level, pLI and genome baseline in prioritization of de novo LGD and D-mis variants among top genes 
ranked by each individual metrics, excluding known risk genes used in A-risk training. D-mis is 
defined by REVEL score ≥ 0.5. The de novo variant data is compiled from 8838 published trios of 
exome sequencing studies. (A) Enrichment is the ratio of observed number of de novo variants to the 
expected number of de novo variants estimated by background mutation rate in top ranks, ranging 
from top 1000 to top 4000 genes. (B) Precision and true positives compared in top ranks. True 
positives, which are the difference value between observed number of de novo variants and the 
expected number, represent the recall since the true number of total causal variants is unknown. 
Precision is computed as dividing true positives by the observed number. Genome baseline is the grey 
star in the plot. C-D, comparison of A-risk to mouse brain expression level and genome baseline in 
prioritizing de novo variants in non-constraint genes with pLI<0.9, excluding known risk genes. pLI is 
excluded from the comparison because it is used in stratifying non-constraint genes. (C) Enrichment 









Figure 3.6 A-risk has better performance than other two methods in prioritizing de novo 
variants. A-B, Compare A-risk to Krishnan 2016(Krishnan et al., 2016) and D-score(C. Zhang & 
Shen, 2017) in enrichment, precision and true positives of de novo LGD and D-mis variants 
prioritized in top ranks by each method, excluding all known risk genes. C-D, Compare the three 





 3.2.3 A-risk informs prior estimation in autism risk gene discovery 
TADA and extTADA (X. He et al., 2013; Nguyen et al., 2017) are empirical Bayesian 
methods used in previous genetic studies of autism(De Rubeis et al., 2014; Satterstrom et al., 
2020) to identify candidate risk genes based on burden of de novo variants. A key feature of such 
empirical Bayesian method is that it estimates parameters of priors, including mean relative risk 
(R) and prior probability (π) of being a risk gene, from the data. We reasoned that metrics 
associated with plausibility of autism risk, such as A-risk and gene constraint (pLI), could be 
used to improve prior estimation in an empirical Bayesian framework. To this end, we stratified 
a total of 18663 protein-coding genes by A-risk score 0.4 and pLI cutoff 0.9, resulting in 4 
quadrants of genes (Figure 3.7A): 1195 constrained genes with high A-risk score (quadrant A), 
1842 constrained genes with low A-risk score (quadrant B), 1444 non-constrained genes with 
high A-risk score (quadrant C) and 14182 non-constrained genes with low A-risk score (quadrant 

















NR2F1 1 0.68 A 1, 1 0.07 TRUE 
Bosch-Boonstra-Schaaf 
Optic Atrophy Syndrome 
with autistic manifestation 
(C. A. Chen et al.) 
NR4A2 1 0.43 A 1, 1 0.09 TRUE Levy 2018 (Levy et al.) 
CLCN4 1 0.59 A 0, 3 0.015 TRUE 
Raynaud-Claes syndrome 
(OMIM 300114) with 
autistic features 
PRKAR1B 0.18 0.43 C 1, 2 0.06 TRUE 
Additional damaging 
variants in Ruzzo 2019 
(Ruzzo et al.) 
GIGYF1 0 0.56 C 5, 0 1e-5 TRUE  
HNRNPU 1 0.48 A 1, 1 0.09 TRUE Mosaic mutations (Lim et al.) 
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D); then we estimated prior parameters by extTADA in each quadrant of genes, using previously 
reported de novo LGD and D-mis variant data from 8838 trios(R. Chen et al., 2017; Feliciano et 
al., 2019; Iossifov et al., 2014; Satterstrom et al., 2020; Takata et al., 2018; Yuen et al., 2017). 
Consistent with previous simulation(Iossifov et al., 2014), in unstratified analysis, π is about 
0.04, corresponding to 750 risk genes in total. In stratified analysis, π decreases from quadrant A 
to quadrant D (Figure 3.7B). Constrained genes stratified by A-risk ≥0.4 in quadrant A have 
Figure 3.7. Prior estimation in stratified extTADA analysis. (A). gene groups defined by pLI and 
A-risk: A: pLI≥0.9 and A-risk≥ 0.4; B: pLI≥0.9 and A-risk <0.4; C: pLI<0.9 and A-risk≥0.4; D: 
pLI<0.9 and A-risk<0.4. (B). Risk gene proportions (π) in stratified gene groups estimated from 
MCMC. Modes are indicated by small boxes in the middle and the upper and lower bars indicate 95% 
confidence intervals. (C). Relative risks (γ) of genes in each stratified group estimated from MCMC. 







greater π and R than genes with low A-risk scores in quadrant 
B (Figure 3.7C). Genes in quadrant C and D have similar π, 
but quadrant C genes have a substantially greater R that D 
genes. Overall, A-risk informs the estimation of those priors in 
both constrained and non-constrained genes. 
The extTADA methods calculates a Bayes factor (BF) 
and posterior probability of association (PPA) for each gene, 
and then converts PPA to FDR (false discovery rate) to 
identify candidate risk genes. Common FDR procedures are 
designed to control the proportion of false positives among discoveries. However, with a large 
number of known risk genes ranked among the top by PPA, the estimated FDR of novel genes 
will be smaller than their true values, considering the true FDR of known genes is 0. This will 
lead to inflation of the support for novel candidate genes (Kaplanis et al., 2020). To address this 
issue, we excluded 90 known genes with SFARI gene score 1 or 2 in FDR estimation 
(Supplementary Table 3.5). The stratified analysis yielded 71 candidate genes passing FDR ≤0.1, 
whereas unstratified analysis yielded 44 genes. Among these genes, 38 were identified 
exclusively by the stratified approach, 11 were exclusively found by the unstratified approach, 
and 33 were shared (Figure 3.8). Previous studies have shown that autism risk genes are often 
pleiotropic and implicated in other neurodevelopmental disorders (NDD) (Coe et al., 2019; 
Cross-Disorder Group of the Psychiatric Genomics Consortium. Electronic address & Cross-
Disorder Group of the Psychiatric Genomics, 2019; Myers et al., 2020; Satterstrom et al., 2020). 
We obtained candidate NDD genes from a recent study(Kaplanis et al., 2020) to seek support of 
the candidate autism genes. Among the 38 genes identified only in stratified approach, 13 are 
Figure 3.8 Stratified extTADA 
analysis by A-risk and pLI 
identifies more candidate risk 
genes of autism. The numbers in 
the Venn diagram show the number 
of genes identified by stratified 
analysis exclusively (38), by un-
stratified analysis exclusively (11), 
and by both approaches (33). 
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significantly implicated with NDD. In contrast, only 1 out of the 11 unstratified-exclusive genes 
is implicated with NDD (Figure 3.9 and Supplementary table 3.6). Among the candidate genes 
that are also implicated with NDD, several are notable with additional support from other studies 
on autism or syndromes with autistic features, such as NR2F2, NR4A2, HNRNPU, CLCN4, and 
PRKAR1B (Table 3.3). Candidate risk genes located in quadrant C, such as GIGYF1 and 
PRKAR1B, are among the small number of candidate genes that are not constrained (pLI ~ 0).  
 
3.2.4 Autism risk genes are highly expressed in deep-layer excitatory neurons in cortex  
Previous studies have investigated autism risk by cortex laminar architecture. However, 
studies based on co-expression analysis (Parikshak et al., 2013; Willsey et al., 2013) or 
neurochemical experiments (Stoner et al., 2014; Trutzer, Garcia-Cabezas, & Zikopoulos, 2019) 
Figure 3.9 Additional support of candidate novel autism risk genes identified by stratified 
or unstratified extTADA analysis with significant genes in neurodevelopmental disorders 
(NDD) identified by Kaplanis et al 2020. Among 33 genes identified by both stratified and 
unstratified extTADA, 23 (70%) are implicated with NDD; 14 genes out of 38 (37%) identified 
exclusively by stratified extTADA are implicated with NDD, whereas only 1 out of 11 (9%) 
exclusively identified by unstratified extTADA is associated with NDD. 
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reported conflicting conclusions, that either deep or superficial layers of cortex are associated 
with autism. These early studies were based on a small number of high-confidence autism risk 
genes. Here we revisit the question with a much larger list of high-confidence candidate genes 
and single cell RNA-seq data. We obtained a single-nucleus RNA-seq data set of the middle 
temporal gyrus (MTG) of adult human cortex with clear laminar layer information (Hodge et al., 
2019).  The expression level of those 90 SFARI score 1 or 2 genes and 71 novel candidate risk 
genes is shown in the heatmap in Figure 3.10A. Hierarchical clustering based on the expression 
data forms four major clusters of genes. Genes in cluster 1 show very little expression in most 
cell types, except that TBR1, RORB, MEIS2, PTCHD1, FEZF2 and NR4A2 are sparsely 
expressed in subtypes excitatory neurons and RELN and PCDH19 are highly expressed in 
subtypes of inhibitory neurons. Cluster 2 genes have more specific expression in deep-layer 
excitatory neurons. Genes in cluster 3 are expressed more widely in neuronal cell types with 
even higher expression in excitatory neurons at deep layers of MTG. Genes in cluster 4 have 
high expression in almost all the neuronal cell types in MTG. Mapping quadrant gene groups 
defined by A-risk and pLI into those 4 distinct expression clusters reveals that both cluster 3 and 
4 are dominated by quadrant A genes (33 out of 47 genes and 29 out of 32 genes, respectively). 
Cluster 2 contains the largest portion of quadrant C genes (10 out of 16 genes, Figure 3.10B). 
Consistent with pLI value distribution, a larger fraction of genes in cluster 2 have higher 
observed to expected (O/E) ratio of LoF mutations in gnomAD (genome aggregation 
database)(Karczewski et al., 2020) compared to genes in other clusters (Figure 3.10C). Overall, 
excitatory neurons project from or to deep layers have high expression of the largest subset of 
known and candidate risk genes.  
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The heatmap of expression fraction in the same order of genes using the two fetal data 
sets in our model are shown in Figure 3.11. There is no layer information with the fetal data. 
Nevertheless, the expression patterns of candidate risk genes in the two fetal data sets generally 
follows the organization in the adult cortex data, especially for fetal prefrontal cortex. 
Additionally, 14 out of 24 cluster 1 genes with little expression in adult cortex neuronal cells 
have fraction expression ≥0.5 in at least one cell type in fetal prefrontal cortex, suggesting a 






























In this study, we developed a new method, "A-risk", to predict plausibility of autism risk 
genes based on single-cell expression patterns in human fetal midbrain and prefrontal cortex. A-
risk was trained using known autism genes. A-risk score reflects the similarity of the cell-type-
specific expression pattern of a gene to known autism genes in aggregation. It achieves superior 
performance in prioritizing de novo risk variants, especially in genes that are less intolerant of 
Figure 3.10 Most autism risk genes have high expression in deep-layer excitatory neurons in 
prefrontal cortex. (A) Hierarchical clustering 90 known autism risk genes and 71 novel candidate 
genes by expression level in cell types from adult cortex middle temporal gyrus (MTG) with laminar 
information. Genes (shown in rows) form 4 major clusters, labeled from 1 to 4 on the left. The dash 
line marks the height cutting the hierarchical tree. Cell types are clustered as well and are labels in the 
format as “major cell type.located layers.marker genes”. Exc, excitatory neurons. Inh, inhibitory 
neurons. Astro, astrocytes. OPC, oligodendrocyte precursor cells. Oligo, oligodendrocytes. Micro, 
microglia. Endo, endothelial cells.  The color (blue to red) of the heatmap indicates expression level of 
a gene in the cell type, calculated as the fraction of cells that have ≥1 UMI mapped to the gene in the 
cell type. Almost all genes in cluster 1 have low expression in all cell types. Most genes in cluster 2 
are specifically expressed in excitatory neurons in deep layers (layer 4 to 6). Cluster 3 genes are highly 
expressed in deep excitatory neurons and have expression in most of neuronal cell types.  Cluster 4 
genes are highly expressed in almost all neuronal cell types.  Quadrant gene groups stratified by Frisk 
and pLI are labeled by the color bar on the right side with A, B, C and D represented by orange, 
purple, yellow and green. (B) Number of known or candidate risk genes from quadrant gene groups in 
each expression clusters. Cluster 1 is enriched with quadrant B genes (high pLI and low A-risk); 
cluster 2 is enriched with quadrant C genes (low pLI and high A-risk); cluster 3 and 4 are enriched 
with quadrant A genes (high pLI and high A-risk).  (C) The distribution of observed over expected 
(O/E) number of loss of function variants in gnomAD database in the 4 expression clusters. Cluster 2 




  A B 
Figure 3.11 Heatmap of expression level of known and candidate risk genes in fetal midbrain (A) and 
prefrontal cortex (B). Row orders are arranged as same as Figure 3.8.  Cell types in midbrain are labeled as 
“h(human)cell type names_week” and cell types in prefrontal cortex are labeled as “major cell type 
name_sub clusters_gestational weeks”, in concordance with original data. DA, dopaminergic neurons. NbM, 
medial neuroblast. OMTN, oculomotor and trochlear nucleus. NbGaba, neuroblast GABAergic. Gaba, 
GABAergic neurons. NbML, mediolateral neuroblasts. ProgFPL, progenitor lateral floorplate. ProgM, 
progenitor midline. RN, red nucleus. Rgl, radial glia-like cells. OPC, oligodendrocyte precursor cells. NProg, 
neuronal progenitor. Endo, endothelial cells. Peric, pericytes. ProgBP, progenitor basal plate. ProgFPM, 
progenitor medial floorplate. NPCs, neural progenitor cells. Exneurons, excitatory neurons. 
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 loss of function variants. Furthermore, A-risk is complementary with gene constraint metric 
(pLI) for improving estimation of priors using an empirical Bayesian association method. 
Applying it to published de novo variant data, we identified 71 novel candidate risk genes, an 
increase of 27 genes over the results using the same statistical method without stratification of 
genes by either A-risk or pLI.  
 Both inhibitory and excitatory neurons in the prefrontal cortex strongly contribute to A-
risk prediction during fetal stages, consistent with previous theory of excitatory and inhibitory 
imbalance in the prefrontal cortex disrupting neural communication(Rubenstein, 2011; 
Zikopoulos & Barbas, 2013). GABAergic inhibitory neurons in midbrain have been identified as 
the most significant contributing feature to A-risk prediction, implicating a potential role of 
midbrain in autism pathogenesis that has been understudied.  
Early functional and co-expression network studies (Chang et al., 2015; Willsey et al., 
2013) based on a small number of high-confidence autism risk genes have revealed convergence 
on excitatory neurons in deep-cortical layers, however, another co-expression network analysis 
(Parikshak et al., 2013) found significance in excitatory neurons in superficial cortical layers. 
With a much larger number of high-confidence risk genes, we revisited the role of neuronal cell 
types in six different cortical layers. Based on a large single nuclei RNA-seq data set from adult 
cortex, we observed that deep-layer excitatory neurons have high expression of the vast majority 
of known and candidate autism risk genes, while other neuronal types or neurons in superficial 
layers have high expression of a much smaller subset of these genes. Since the excitatory 
neurons residing in layer 5 or 6 of cortex extend their axons into other regions of brain and 
communicate between cortex and other critical regions (Molyneaux, Arlotta, Menezes, & 
Macklis, 2007; Rubenstein, 2011), disruption of deep-layer excitatory neurons more likely 
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affects signal transmission and communication across different brain regions. Taking account of 
gene mutation intolerance (pLI) and expression similarity to known autism genes (A-risk), the 
candidate risk genes with high A-risk but low pLI (i.e. quadrant C), such as GIGYF1 and 
MBOAT7, are much more likely to have specific expression in deep-layer excitatory neurons. 
Interestingly, a recent study (Satterstrom et al.) showed GIGYF1 was the most autism-specific 
gene among all candidate autism risk genes based on frequency of disruptive de novo variants in 
either autistic or severe NDD cohorts. This suggests an association of deep-layer excitatory 
neurons and autistic conditions that do not involve severe NDD conditions such as intellectual 
disabilities. We expect that this hypothesis will be tested in future studies with independent high-
resolution single cells or neural circuit expression data, larger set of high-confidence risk genes, 
and autism cohorts with comprehensive NDD phenotyping.  
The majority of genes in quadrant C are located in expression cluster 2, where a higher 
proportion of genes shows increased observed to expected (O/E) ratio of LoF mutations, 
suggesting quadrant C genes are less intolerant to LoF mutations or may be incompletely 
penetrant. The genes that have high A-risk and high pLI (quadrant A) are more likely to have 
high expression in a wide range of cell types. Candidate risk genes in cluster 1, among which 16 
genes out of 33 in total have high pLI but low A-risk (quadrant B), have sparse expression in 
adult cortex but more expression in fetal prefrontal cortex, indicating those autism risk genes can 
take effect at limited time points and places. 
 A-risk directly utilized single-cell transcriptomic data as the input of the machine 
learning model to learn expression patterns from known risk genes. Expression patterns inferred 
from single-cell RNA-seq data have better resolution than bulk sequencing data with fine-
grained cell-type heterogeneity and developmental temporal information. To integrate 
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transcriptomic information in risk gene discovery in a principled way, we used A-risk in an 
empirical Bayesian framework to improve prior estimation based on genetic data. This approach 
yielded 27 more candidate risk genes than the original Bayesian approach using only genetic 
data. With increased sample sizes in the future, A-risk can also be used as informative covariates 
to improve FDR estimation (Ignatiadis, Klaus, Zaugg, & Huber; M. J. Zhang, Xia, & Zou) in 
frequentist approaches for risk gene discovery. 
A-risk is currently limited by the availability of comprehensive single-cell expression 
profiles across all critical human brain regions and developmental stages. Profiling neuron cells 
is uniquely challenging since the information in extended projections and axons can be lost 
during sample preparation in single-cell RNA-seq. Even though the data we used in the A-risk 
model is from fetal stages, when extended axons of neurons have not been prolonged, we should 
still interpret with consideration that there could be some genes missed in the data. New single-
nucleus RNA-seq and subcellular transcriptomic profiling techniques and data sets from ongoing 
projects such as Allen Brain Institutes (Miller et al., 2014) and Human Cell Atlas (Han et al., 
2020) will help to address this issue (Fazal et al., 2019; Kebschull et al., 2016). Additionally, A-
risk is a supervised learning approach, and inevitably it biases towards genes with similar 
expression patterns to known risk genes in the training. Unsupervised approaches could assist in 
addressing the problem. Finally, abundant and specific expression is not sufficient to define a 
gene as a risk gene. Other factors such as functional redundancy (Kafri, Levy, & Pilpel, 2006) 
and protein complex formation (Marianayagam, Sunde, & Matthews, 2004) that determine 
whether a high-expression gene is a bottleneck in a system, also play a role in the genetic impact. 





3.4 Material and methods 
3.4.1 Data collection and preprocessing 
 In this study, we integrated human fetal brain single-cell RNA-seq data from two 
publications: (1) midbrains from 6 to 11 weeks (La Manno et al., 2016) and (2) prefrontal 
cortexes from gestational weeks 8 to 26(Zhong et al., 2018). To integrate these two data sets, 
first, we obtained the UMI counts of single cells from their published data. Second, we directly 
utilized the cell type clusters and time points documented in the publications and calculated the 
expression fraction of each gene in each cell type at a particular time point. We combined each 
individual cell type and time point together to generalize one feature in the integrated data. The 
expression fraction is defined as, for a particular gene in a cell type at a developmental time 
point, the number of cells having the gene expressed (UMI >= 1) divided by the total number of 
cells grouped in the cell type. La Manno et al., 2016(La Manno et al., 2016)  reported 26 cell 
types across 6 developmental time points, including an unknown cell type ("Unk") where those 
cells cannot be assigned to any known clusters. We excluded Unk cells in the analysis. Zhong et 
al., 2018 reported clustered 35 cell types through 9 time points. Furthermore, we also excluded 
cell types with fewer than or equal to 10 cells. In total, we compiled 95 features in the combined 
data set, including 47 from La Manno et al., 2016 and 48 features from Zhong et al., 2018. 
 We obtained known autism risk genes with score of 1 or 2 in the SFARI 
database(Abrahams et al., 2013) (https://gene.sfari.org/database/human-gene/, version released 
on 08/29/2019) as the positives for model training. There are 3 genes BAZ2B, MSNP1AS and 
TBR1 not present in the single-cell expression data, so we excluded them in the positive training 
set. For the negatives for model training, we collected genes harboring at least 1 de novo LGD 
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variant in controls from an exome-sequencing study on autism(Iossifov et al., 2014). Two genes 
(KDM5B and CACNA1H) are present in both the initial positive and negative sets. We removed 
these 2 genes from the negative set. In total, we compiled 88 genes in the positive training data 
set and 154 genes in the negative training data set. The full list of training genes is available in 
Supplementary table 3.1.  
 
3.4.2 Machine learning approaches to predict autism risk genes 
 A-risk (“Autism risk”) is based on a supervised machine-learning method, gradient 
boosting tree (GBT) (Friedman, 2002). The goal of the model is to find a function F*(x) mapping 
"input" x to "output" y, such that the expected value of some specified loss function Ψ(y, F(x)) is 
minimized, 
F*(x) = arg min
𝐹𝐹(𝑥𝑥)
𝐸𝐸𝐸𝐸, 𝑥𝑥Ψ(𝐸𝐸,𝐹𝐹(𝑥𝑥)). 
GBT is estimating F*(x) by an additive update to the form 
F(x) = ∑ 𝛽𝛽𝑚𝑚ℎ(𝑥𝑥)𝑀𝑀𝑚𝑚=0 , 
and specifically updating the previous model with the error estimated in the previous step 
Fm(x) = Fm-1(x) + 𝛽𝛽𝑚𝑚ℎ(𝑥𝑥), 
where the functions ℎ(𝑥𝑥) are base learner functions and m = 1,2,...,M is iteration of the model. 
𝛽𝛽𝑚𝑚 is the current "pseudo"-residual, where 
𝛽𝛽𝑖𝑖𝑚𝑚  =  −
𝜕𝜕Ψ�𝐸𝐸,𝐹𝐹𝑚𝑚−1(𝑥𝑥)�
𝜕𝜕𝐹𝐹𝑚𝑚−1(𝑥𝑥)
|𝑥𝑥 = 𝑥𝑥𝑖𝑖, 𝐸𝐸 =  𝐸𝐸𝑖𝑖 , 
for all i = 1,2,...,N, which is the number of training data points. Then we can estimate the optimal 
𝛽𝛽𝑚𝑚 and base learner ℎ(𝑥𝑥) by fitting 





 We train the model using the training gene set and features derived from single cell data 
sets. To implement the gradient boosting tree machine, we used the python package 
"sklearn.ensemble.GradientBoostingClassifier" with parameters of "n_estimators" as 300, 
"learning_rate" as 0.05 and "max_depth" as 1. We assessed the performance of the model by 5-
fold cross validation. In each cross validation, the model randomly selected 20% of the training 
gene set to serve as a test set for validation and the rest of the genes were used to train the model. 
We implemented the python package "sklearn.metrics.roc_curve" to calculate the true positive 
rate, false positive rate, and to plot the ROC curve and calculate AUC values. After training, we 
predicted the probability for each protein-coding gene in the genome being a positive gene (i.e. 
plausibility for being an autism risk gene) by the trained model. The final A-risk score is the 
average probability from the 5-fold training and prediction. The complete A-risk score is 
available in Supplementary table 2.  
 "Feature importance" is derived from the gradient boosting tree model using the function 
"feature_importances_". In the GBT model, parameters of base learner functions are the splitting 
variables and corresponding split points defining the tree. The "feature_importances_" is a 
normalized estimate of the predictive power of a particular feature by combining the fraction of 
samples the feature contributes to and the decrease in impurity from splitting them (Louppe, 
2014). The final feature importance value for each selected feature is the average from the 5-fold 
training and prediction. All selected features with non-zero feature importance are listed in 




3.4.3 Comparison of A-risk to other metrices in prioritizing de novo LGD variants 
 We tool two approaches to compare the ability of A-risk and other metrics in 
prioritization of de novo variants. With each metric, we first rank all genes; then in all genes 
above a certain rank threshold (e.g. 1000, 1500, 2000, etc), we estimated the "enrichment of de 
novo variants", "precision", and "true positives". The formulae to compute these estimates are as 
following: 
 For any gene i, the number of expected de novo variants in each gene, Ei, was calculated 
as: 
     Ei = 𝟐𝟐 ×  𝑵𝑵 × ri 
where N is the number of trios in the compiled data sets and ri is gene-specific background 
mutation rate. Here we tested on de novo gene-likely disrupting (LGD) variants and deleterious 
missense (D-mis) variants (Figure 3.4). LGD variants include nonsense, frameshift and canonical 
splice site mutations and D-mis variants are defined as variants with REVEL (the Rare Exome 
Variant Ensemble Learner) score >= 0.5 (Ioannidis et al., 2016). For each gene, ri  is the sum of 
background mutation rate of LGD mutations plus D-mis mutations. 
 The background mutation rate per gene of each mutation type was obtained from a 
previous described mutation model (Carlson et al., 2018; Samocha et al., 2014). Briefly, the 
seven-nucleotide sequence context was used to determine the probability of each base in 
mutating to each other possible base. Then, the mutation rate of each functional class in each 
gene was calculated by adding up point mutation rates in the longest transcript. The rate of 
frameshift indels was presumed to be 1.25 times the nonsense mutation rate and the rate of genes 
located on chromosome X is further adjusted according to female-to-male ratio in the de novo 
data set (C. F. Wright et al., 2015).  
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 For a set of genes, the enrichment of de novo variants, D, was calculated as: 
      𝑫𝑫 =  𝑴𝑴
∑ 𝑬𝑬𝒊𝒊𝒊𝒊
 
where M is the total number of observed de novo LGD or D-mis variants in this gene set.  In this 
study, we compiled results from multiple whole exome studies on autism spectrum disorders, 
including total of 8838 trios from Simons Simplex Collection (SSC) (Iossifov et al., 2014), 
Autism Sequencing Consortium (ASC) (Satterstrom et al., 2020), SPARK Pilot (Feliciano et al., 
2019), MSSNG (Yuen et al., 2017), Takata et al., 2018 (Takata et al., 2018) and Chen et al., 
2017 (R. Chen et al., 2017) cohorts.  
           For any gene set, the number of detected true positives, TP, was calculated as: 
             𝑻𝑻𝑻𝑻 = 𝑴𝑴 −  ∑ 𝑬𝑬𝒊𝒊𝒊𝒊  
           For any gene set, the precision (positive predictive value), PPV, was calculated as: 
                PPV= M - ∑ Eii
M
 
 For each metric (A-risk, pLI etc.), a set of genes were selected based on the rank of genes 
by each individual metric, such as top 1000 genes or top 2000 genes, etc. The genome baseline is 
defined by all the genes in the genome. For the first estimate, enrichment of de novo variants, D, 
was calculated for any set of top-ranked genes, and then enrichment values were plotted and 
compared, as shown in Figure 3.4A. For the second estimate, the number of detected true 
positives, TP, and the precision (true discovery rate), PPV, were calculated for any set of top-
ranked genes. TP and PPV were plotted and compared, as shown in Figure 3.4B. Recall would 
be calculated as R = TP/N, where N is the total number of true positives (N). Since N is unknown 
but a constant, TP is proportional to R. Therefore, we use TP as a proxy of recall. To avoid 
inflation of A-risk performance, we excluded all the known autism risk genes used in A-risk 
training during calculation of all above estimates. Although there are different numbers of genes 
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predicted by each method, we compared all the methods with 18663 protein-coding genes, 
replacing missing scores with the median of each corresponding metrices.  
 To exam the potential of A-risk in prioritizing de novo variants in non-constrained genes, 
we limit the estimates on genes with pLI score <= 0.9 in each top rank of genes (Figure 3.5C and 
D). We excluded pLI as a metric for comparison in those figures since pLI was used to stratify 
constraint and non-constraint genes. Furthermore, we also compare A-risk with the other two 
metrices D-score and Krishnan 2016 (Figure 3.6).  
 
3.4.4 Application of A-risk in stratified risk-gene discovery analysis 
 In this analysis, we used an empirical Bayesian model of rare-variant genetic architecture, 
extTADA (Extended Transmission and de novo Association) (Nguyen et al., 2017), which can 
estimate mean effect sizes and risk-gene proportions from the genetic data to identify autism 
candidate risk genes. The extTADA model is developed based on a previous integrated empirical 
Bayesian model TADA (Transmission and de novo Association) (X. He et al., 2013), but it 
advanced the framework by estimating parameters using MCMC (Markov Chain Monte Carlo) 
process so that more accurate estimation on local gene groups can be achieved and confidence 
intervals can be provided.  
 Two major parameters, relative risk of a gene causing a disease γ and the proportion of 
disease risk genes across the local gene groups π, are estimated by the connection to variant fold 
enrichment (FE), which is calculated as the number of observed variants divided by the number 
of expected. Assuming the background mutation rate for each gene is µ, total number of genes in 
the gene set is m and total number of sequenced samples is N, then 
the observed variants, X = πm×2γµN + (1-π)m×2µN 
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the expected variants, Xe = πm×2µN + (1-π)m×2µN 
FE = 𝑿𝑿
𝐗𝐗𝐞𝐞
 = π (γ - 1) + 1, γ ~ Gamma (γ̅ β, β) 
FE can be calculated from the data, parameters  γ , π and β are estimated accordingly using a 
Hamiltonian Monte Carlo (HMC) MCMC method implemented in the "rstan" package 
(Carpenter et al., 2017).  






H1 is alternative hypothesis and H0 is null, where γ = 1. 









where 𝑻𝑻(𝑯𝑯𝑯𝑯) is estimated π, 𝑻𝑻(𝑯𝑯𝑯𝑯) is (1-π ).  
 Assuming the posterior probability of association (PPA), 𝑻𝑻(𝑯𝑯𝑯𝑯|𝑿𝑿) is q, so the posterior 




then per-gene based FDR can be calculated from q0. First, q0 is ranked in an increasing order for 
all the genes, then FDR is the sum of total q0 smaller than the current rank @k divided by the 
total number of genes k with smaller q0: 
𝐹𝐹𝐹𝐹𝐹𝐹@𝑘𝑘 =  
∑ 𝒒𝒒0i𝑖𝑖 = 1𝑘𝑘
𝑘𝑘
 
 To inform the parameter estimation with prior knowledge, we stratify the whole genome 
into 4 quadrants by A-risk score 0.4 and pLI score 0.9, so extTADA can estimate local 
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parameters in each 4 groups and better characterize properties for individual groups. Specifically, 
quadrant A consists of genes with A-risk >=0.4 and pLI >=0.9. Genes in quadrant B are in A-risk 
<0.4 but pLI >=0.9. Genes in quadrant C have A-risk >=0.4 but pLI <0.9, and the rest of the 
genes are assigned to quadrant D. We applied the extTADA model to each quadrant of genes to 
estimate the parameters and calculate PPAs. Then we combined the PPAs of 4 quadrants 
together to calculate a final genome-wide FDR (false discovery rate). To make FDR estimation 
of novel risk genes more accurate, we excluded known autism risk genes used in training A-risk 
model in FDR calculation, as most of these genes are ranked in top by PPA and including them 
in FDR calculation with deflate FDR values of novel risk genes. In parallel, we also inputted all 
genes into extTADA without stratification by A-risk or pLI to obtain an unstratified version of 
the same analysis, so that we can show the advantage of integration of biological information in 
genetic association studies. We used the same de novo variant data from 8838 trios and 
background mutation rate data as described above. 
 
3.4.5 Expression pattern clustering of known and candidate autism risk genes  
 We compiled the 71 novel candidate risk genes that pass FDR <=0.1 in stratified 
extTADA analysis together with 90 known risk genes (The gene MSNP1AS is missing in the 
input data for extTADA, because it is a non-coding gene.) and investigated the expression 
pattern of all those risk genes in a single-cell RNA-seq data of adult human cortex (Hodge et al., 
2019). The data was pre-processed as described above and the expression fraction for each cell 
type was pre-computed from read-count data downloaded from the publication. Hierarchical 
clustering was performed using "ComplexHeatmap" package in R based on "Euclidean distance" 












 This thesis discussed about two methods, Episcore and A-risk. The methods are built on 
data mining on functional genomics using machine learning approaches. Episcore has 
successfully predicted haploinsufficient genes by learning on analogous epigenomic patterns 
present in known haploinsufficient genes, such as broader peaks of H3K4me3 epigenomic 
modification and more frequent interactions between promoters and enhancers. We compiled 
about 360 features from various epigenomic modification in multiple human tissues or cell lines. 
By using Episcore, we can identify disease risk genes that take action through 
haploinsufficiency, which is the major mechanism when mutations occurred in risk genes. A-risk 
is a method developed specific to autism, where we learned from the single-cell expression 
patterns of known autism risk genes, and predicted on other genes vulnerable to autism genetic 
risks. We integrated two single-cell RNA-seq data sets from human fetal midbrain and prefrontal 
cortex, consisting about 4000 cells in a wide range of developmental stages. A-risk prioritized 
about 2500 genes and there is a significant enrichment of de novo LGD and deleterious missense 
mutations from autism patients among the top 2500 genes.  
 The two methods developed from functional genomics provide additional and orthogonal 
information for traditional genetic analysis, combining which gained improved power to identify 
and better interpret genetic risks. The most-adapted pLI metric is developed by measuring 
depletion of LoF mutations in healthy populations and only utilized WES data. By combining 
Episcore and pLI, the meta score can improve the precision and true positives to much higher 
levels, indicating the two methods are complementary and providing diverse biological 
information. The advantage of plugging A-risk into discovery of autism risk genes is even more 
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prominent. After inputting A-risk as prior information for parameter estimation in extTADA 
analysis, we identified 27 more risk genes resulting in total of 71 novel risk genes except for all 
known risk genes, with current limited sample size.  
 Data mining on functional genomics can directing infer disease etiology. The common 
obstacles of genetic analysis lie in lack of linkage to functional interpretation, so when we found 
a risk gene with strong statistic evidence, it is hard to find mode of action and implicated cell 
types, tissue or developmental time point. In both Episcore and A-risk, we predict on risk genes 
directly from their regulatory or transcriptomic landscapes, therefore we can interpret disease 
mechanism altogether. In Episcore, the importance directly derived from the random forest 
model shows that active promoters and enhancers have more contribution to haploinsufficiency 
than repressive promoter features, indicating regulations for haploinsufficient genes may come 
from active promoters and enhancers more. Similarly, we also inferred from the A-risk model 
that GABAergic neurons at week 9 in midbrain and excitatory neurons at week 12 in prefrontal 
cortex are the most contributing cell types to autism risk prediction, which means that those may 
be the most vulnerable cell types in autism etiology providing directions for future functional 
studies. In summary, we found that integrating functional genomic data with genetic analysis is 
effective and tantalizing in facilitating genetic discoveries in era of computational biology.  
 In the following section, I am going to talk about future steps to improve our prediction 
models and methods. In addition, I am going to propose other directions to integrate functional 






4.2.1 Transmission risk analysis in A-risk gene discovery 
Even though A-risk autism genes are predicted by training on risk genes identified by de 
novo variants, we still interested in how A-risk risk genes can characterize autism genetic 
architecture. A current ongoing analysis working on the SPARK (Simons Powering Autism 
Research) project, which consist of WES data from more than 10,000 autism cases from about 
9,000 families, analyzed the over-transmission rare LoF variants in multiple functional gene sets 
to compare for the most efficient metrics to prioritize rare inherited variants. They have 
compared between the number of transmitted and un-transmitted rare LoF variants from parents 
to affected offspring. The background gene set is composed of genes with pLI score > 0.5 as 
preliminary filtering and they selected several functional gene groups beyond it. A-risk candidate 
genes are selected by predicted score > 0.4 and are compared to the following gene sets: (1) 
Brain enriched genes are a specific group based on a transcriptome analysis, that expressed in 
brain tissues with larger than 5 times median expression in other tissues (Fagerberg et al., 2014). 
(2) SynaptomeDB is a database collecting proteome comprising the synaptome  (Pirooznia et al., 
2012), a critical implicated regulome in autism. (3) FMRP interacts with transcripts encoding 
pre- and postsynaptic proteins implicated in autism, so target genes of FMRP are potential 
convergent regulome for autism risks (Darnell et al., 2011). (4) Target genes of the autism-
associated chromatin modifier CHD8 are also enriched for other ASD risk genes and converge in 
ASD-associated co-expression networks in human midfetal cortex (Cotney et al., 2015). (5) 
Targets of CELF4 are also enriched in the processes regulating synaptic plasticity and 
transmission (Wagnon et al., 2012). (6) The LOEUF metric stands for the “loss-of-function 
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observed/expected upper bound fraction”, which also measures the intolerance of a gene to 
variants but provides better significance measure than pLI (Karczewski et al., 2020). In this 
analysis, they found that A-risk explains the highest proportion (~60%) of over-transmitted 
events across all other 6 gene groups and achieves the highest precision as well, indicating A-risk 
candidate gene set performs best in prioritizing rare inherited LoF variants.   
Following the same logic, we can also investigate the enrichment of common risk 
variants in A-risk candidate genes. Since A-risk genes are predicted on expression patterns of 
genes identified by de novo variants, higher enrichment of over transmission in A-risk predicted 
autism genes suggests inherited and de novo genetic risks can converge on common 
transcriptomic network or pathways in affected cell types. To further modify A-risk model to 
investigate the role of rare inherited variants, we can exclude positive training genes with nearly 
complete penetrance to train the machine learning model and find more risk genes vulnerable to 
inherited variants and identify implicated cell types.  
 
4.2.2 The integration of more comprehensive data sets 
The capacity of Episcore can be definitely improved by the availability of cell-type 
specific epigenomic data. A recent study using single-cell ATAC-seq (Assay for Transposase-
Accessible Chromatin using sequencing) technique has profiled chromatin accessibility 
of >75,000 single cells from eight distinct arears of developing human forebrain (Ziffra et al., 
2020), and the data can be adapted in Episcore model to gain more insights on regulatory 
mechanism on gene expression in the resolution of cell types of developing human brain. Their 
finding also showed the important contribution of specific and dynamic chromatin state to 
emerging cell-type diversity and cell fate specification, indicating additional cell-type 
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epigenomic information can be leveraged by Episcore model. Furthermore, cell-type 
epigenomics of mouse cerebrum have been profiled as well (Li et al., 2020), which we can also 
integrate in the model to better understand mammalian brain regulation.  
In the meantime, another straight forward direction to improve A-risk method is to 
compile and integrate more single-cell transcriptomic data. First, data from other tissues or areas 
of human brain can be combined to investigate genetic risk impact in other brain structures, for 
example, spatial and single-cell data from striatum (Martin et al., 2019) and cerebellum 
(Aldinger et al., 2020). Second, we can collect data from other important developmental stages. 
In our original A-risk model, we didn’t include a considerable number of neuronal cells during 
early second trimester stage, but a recent study has sequenced on 40,000 cells in human 
neocortex during mi-gestation (Polioudakis et al., 2019), with which can help complete the time-
point gap in the previous A-risk model. We also believe that with more data collected in 
consortium projects like Allen Brain Map (Miller et al., 2014), the whole picture of human brain 
transcriptomics can be accessible in the near future.  
Besides to improve the two methods we have developed, the machine-learning approach 
to predict on genetic risks can be applied to other diseases. There are aggregative studies 
profiling comprehensive transcriptomics across all major human organs to build a human cell 
landscape at single-cell level (Han et al., 2020; S. He et al., 2020). Consortiums like Human Cell 
Atlas (HCA, https://www.humancellatlas.org) has also been working on constructing systematic, 
high-resolution and comprehensive reference maps for all human cells. With more accessible 
data, the framework of Episcore or A-risk can be applied to facilitate risk gene discovery and 




4.2.3 Single-cell RNA velocity Analysis on transcriptional regulation of disease risk genes 
 A recent study brought up a concept, RNA velocity γ  in single cells, to measure cellular 
dynamics using single-cell RNA-seq data (La Manno et al., 2018)(La Manno, 2018). Assuming a 
steady-state abundance of spliced (mature) s and unspliced (nascent) u mRNA molecules 
captured by single-cell RNA-seq technique, this method estimates RNA velocity of a particular 
gene from the snap-shot of expression (t indicates time): 
𝑑𝑑𝒔𝒔
𝑑𝑑𝑑𝑑
= 𝒖𝒖 −  γ 𝒔𝒔  
Where γ is a composite value combining degradation and splicing rates and capturing gene and 
cell-type specific regulatory properties, which can be used as transcriptional dynamic 
measurements and cellular lineage indicators.  
 In Episcore and A-risk, we analyzed the epigenomic and expression pattern of risk genes. 
Higher level of expression or more sophisticated epigenomic regulation that a gene possesses is 
indeed an indicator of functional importance of the gene, but the regulatory dynamics is not 
inferred or leveraged in the model. By combining RNA velocity data in our machine learning 
approach, we can take advantage of the cellular dynamic information to understand the trajectory 
of disease risk genes in cellular differentiation process and identify more informative cell types 
shaping the disease etiology. By analyzing the enrichment of disease risk genes among those 
“driver genes” inferred by RNA velocity, we can also find relevant cell types involved in the 
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